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ABSTRACT
Certain diseases comprise an initial asymptomatic period during which they
can be identified only by a screening test. In many such cases, early detection trans-
lates into benefits of more treatment options and potentially better prognosis. In this
dissertation, we consider the optimal policy to screen for a preclinical disease while
under limited budget. Our objective is to place any given number of screening epochs
over an individual’s lifetime, such that the probability of identifying the disease while
preclinical is maximized. We make mild assumptions about the sojourn times of the
individual in the healthy and preclinical states, and we consider the possibility of
fallible screening tests. We show that a unique optimal sequence of screening times
exist for our model, and that it can be quickly found by any greedy-search algorithm.
We further conduct numerical experimentations by which we identify sensitive model
inputs. We lastly apply our model to breast cancer screening using practical infor-
mation and we investigate additional characteristics of this model.
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1. INTRODUCTION
Certain chronic diseases are characterized by an initial phase with no outward
symptoms on the patients (a.k.a. “preclinical” period). Screening tests are available
to find a disease in its preclinical period. Once a preclinical disease is detected, ben-
efits could be reaped in terms of less aggressive treatment options and/or improved
prognosis. On the other hand, if the disease is left untreated and enters its symp-
tomatic (“clinical”) stage, then the treatment procedures may become much more
involved and chances of long term survival much reduced. Examples of diseases that
comprise such features include hypertension, diabetes, and a collection of cancers
such as breast, cervical, colorectal and prostate cancers.
Despite the general acceptance on benefits of screening, different professional
and governmental organizations are recommending different schedules for the public
to go on screening tests. In the case of breast cancer for example, the American Can-
cer Society recommends all women at ages 40 and over to go on both mammography
and clinical breast exam annually; the National Cancer Institute recommends only
mammography every one or two years beginning at age 40; and the U.S. Preventive
Services Task Force suggests mammography only for women between 50 to 75, and
only biennial exams. International debates over screening policies in terms of their
starting age and their frequency are ongoing.
It is clear that by scheduling many screenings over his/her life, one obtains
an improved potential of detecting a preclinical disease, yet one also incurs higher
cost. In the end, some of the capital spent on screening for one disease might have
been better utilized to treat/screen for other diseases. On the other hand, certain
screening exams are themselves risky, e.g. colonoscopy if not well performed may
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cause perforation of the intestine, bleeding or incontinence, and mammography can
be harmful if the device is not calibrated at its right radiation level. Also complicating
the practice of screening are the side-effects associated with false-positive screening
results. Usually if a screening tests positive, more accurate (and oftentimes more
aggressive) follow-up procedures are required to confirm the case, e.g. biopsy for
breast cancer. As such, a falsely-produced positive result by screening will translate
into additional costs, medical risks, and negative emotions for the patient which are
in fact unnecessary.
In this dissertation, we study the optimal policy to screen for a preclinical
disease while considering cost. We use the term “screening policy” to mean a series
of time points at which an individual is supposed to go on screening exams even
if he/she seems healthy. Our goal is to develop a methodology that could be used
by the public health community to provide informed recommendations for disease
screening.
Our model aims to find the screening policy that detects the preclinical disease
with maximal probability, and we consider cost in terms of a screening budget, which
is defined as the maximum number of screenings allowed in a person’s lifetime. In
implementation, we may solve the model at a variety of budget levels and observe
the performance of the optimal screening policy at each one. This process may be
continued until the best trade-off is met between screening budget and the probability
of detection in the eyes of a decision maker.
We assume known information about the evolvement of the disease and about
the sensitivity of screening exams. In practice such information is not directly col-
lectable and needs to be estimated by rather sophisticated statistical procedures.
Specifically, we assume the population’s healthy sojourn time has a density that is
a log-concave function, and the preclinical sojourn time has a general density on
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infinite support. We also model false-negative screening results by assuming a fixed
sensitivity for all screenings.
The main result is that the model consists of a unique optimal screening
policy, and that this policy can be quickly found by a greedy-search procedure due
to the nice structure of the objective function.
We then numerically conduct a variety of sensitivity analyses on the model
inputs. The results reveal that the variances of the distributions for both disease-
free and preclinical sojourn times play a key role in the performance of the optimal
solution.
We apply our model to the screening of breast cancer. With parameters
assumed to the best of our knowledge, we observe that the equal-interval screen-
ing policy performs rather closely to the optimum. Additionally, we examine the
expected number of screenings (for both disease-free and disease-affected popula-
tions) and the expected lead time (i.e. time gained in diagnosis due to screening for
the disease-affected population). We show with practical evidence that the disease-
free population actually receives many more screening examines compared with the
disease-affected population who is our target. We also show for our particular breast
cancer screening model that the screening policy which maximizes the probability of
screening detection also maximizes the expected lead time to clinical detection.
We want to also point out that our model can be applied to other settings in
which a system that comprises a non-self-announcing “incipient-failure” state and a
self-announcing “hard-failure” state is maintained. One example as such is the infras-
tructure maintenance problem, in which invisible degradations could have occurred
long before they become visible and dangerous.
This dissertation is organized as follows. In Section 2, we review the relevant
literature on preclinical disease screening. In Section 3, we lay down our formulation
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for the optimal screening policy model. The analytical solution to the model will
be shown in Section 4. In Section 5, we present our sensitivity analysis results. In
Section 6, we show our numerical results as we apply our model to breast cancer
screening. Lastly, Section 7 will conclude our research and point out a few directions
for future research.
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2. LITERATURE REVIEW
Model-based studies of asymptomatic disease screening date back to Zelen
and Feinleib (1969). In this pioneering study, the authors develop a statistical model
to estimate the mean lead time for a public screening program. The lead time is
defined to be the time gained in disease detection by screening than it normally
would due to symptoms.
Under considerably strong assumptions, e.g. a single and perfectly sensitive
screening conducted far from the time origin, and a constant prevalence level of pre-
clinical samples in the population over time (so-called “stable disease model”), the
authors derive a mean lead time estimator for the screen-detected population that
is based solely on moments of the population’s preclinical sojourn time distribution.
Zelen and Feinleib (1969) further estimate these moments by information on the clin-
ical incidence rates and preclinical prevalence level of the disease, which are collected
from practice.
The model of Zelen and Feinleib (1969) is applied to data from the Health
Insurance Plan for Greater New York (HIP) program, one of the earliest large-scale
screening trials conducted in the US for better treating breast cancer. The outputs
suggest that the preclinical sojourn time in this case is well-modeled by an exponen-
tial distribution.
Later, Albert et al. (1978a,b) and Louis et al. (1978) present a series of three
reports, in which they mathematically define a large collection of traditional epi-
demiologic terms that are relevant to a preclinical disease. These terms include mean
sojourn time, age-specific incidence rate, age-specific prevalence, lifetime attack rate
and a variety of cohort effects. The definitions are based on a disease progression
5
model that consists of three disease states, namely, disease-free, preclinical and clin-
ical states; and all quantities are expressed in terms of the joint-distribution of a
population’s age mix and its sojourn times in the various states. This disease pro-
gression model is so-called a “natural history model”, for the reason that it considers
only the progression of the disease undisturbed, without say, any early interventions
due to results of screening.
As in Zelen and Feinleib (1969), evaluation of screening programs forms the
goal of an early stream of studies of disease screening. Essential to this is knowledge
about the population’s experience while in the preclinical state, such as the sojourn
time distribution and the sensitivity of screening tests. As these quantities are not
directly observable from practice, estimation of them is the normally the first step
of a program evaluation model.
Walter and Day (1983) and Day and Walter (1984) then adopt the stable
disease model as proposed by Zelen and Feinleib (1969) and continue estimating the
lead time of a screening program. As a generalization, their model considers multiple
screenings and the possibility of false-negative screening results. In particular, the
sensitivity of the screening test is treated as an unknown constant which is also
to be estimated. In Walter and Day (1983), a few statistical distributions for the
preclinical sojourn time are considered, and while applied to the HIP data, the
exponential model again outperforms all others; thus in Day and Walter (1984),
estimates on test sensitivity and the exponential density parameter are applied to
derive the mean lead time. In doing this, each clinical incidence is assigned a zero
lead time value, and the mean is taken over the entire screened population. The
outcome is thus a program-wide mean lead time.
Relaxing the assumption of a stable disease, Lee and Zelen (1998) present the
first work that estimates the time-dependent rates for the population’s preclinical
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incidences. By first recognizing the clinical incidence rates as convolution of the
preclinical state’s incidence rates and sojourn time density, and by assumed knowl-
edge of clinical incidence rates and preclinical sojourn time distribution, the authors
develop a de-convolution approach to infer preclinical incidence rates. As data of
incidence rates are normally generated by age groups in practice, the output of the
de-convolution procedure has the format of a step function.
With this update on the underlying disease progression model, Shen and
Zelen (1999) consider again the estimation of mean screening program lead time yet
with multiple screening modalities and possibly dependent test sensitivities among
them. The statistical model developed is rather intricate, with many parameters
to be estimated on test sensitivities and on the incidence rates and sojourn time
distribution for the preclinical state.
In Parmigiani and Skates (2001), a generalized disease progression model is
considered that allows for dependencies among the population’s sojourn times in the
disease-free, preclinical and clinical states, and that models the population’s deaths
due to other causes, i.e. competing risks, explicitly in each state. This model is first
proposed in Parmigiani (1993) in which the cost-effectiveness of various screening
strategies are compared. By assumed knowledge of clinical incidence rates, preclinical
sojourn time distribution, and overall competing death rates for the population, the
authors develop a de-convolution procedure to obtain preclinical incidence rates as
well as competing death rates for the population while being preclinical. The latter
rates are relevant to evaluating the over-diagnosis effects of a screening program.
Pinsky (2001) estimates preclinical incidence rates and sojourn time distribu-
tions, and tests sensitivity all at once while treating sensitivity as a linear function
of sojourn time in the preclinical state at the time of screening. The de-convolution
procedure consists also of a smoothing method to produce a continuous incidence
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rate function.
Indeed, the lead time has been used by many studies as a performance measure
to evaluate screening programs. Though it reflects the potential for better disease
prognosis, for a total assessment of a screening program, one is more concerned with
the program’s benefit time. The benefit time is defined to be the additional time
of survival a person gets as a result of early disease detection and treatment, and it
should be measured relative to the situation in which the case is found and treated
as a clinical incidence. To evaluate a screening program by its benefit time, a long
follow-up period is required to generate the needed data. Ideally, data collection
should last until all samples in the population die out.
Kafadar and Prorok (1994) develop a statistical model to simultaneously es-
timate the average lead time and benefit time of a screening program. The study
adopts the stable disease model of Zelen and Feinleib (1969), and estimation is done
by relating the screened and control populations’ survival time distributions while
having average lead time and benefit time treated as unknown constants. For each
population, two distributions are considered that measure the survival times from
the start of screening program and start of case treatments respectively. Quite many
simplifications are made in Kafadar and Prorok (1994), such as perfect screening
sensitivity, no competing death risks, and the independence of the survival distribu-
tion with respect to sojourns times in the healthy and preclinical states. Due to the
lack of data from existing screening trials, the authors use simulation to evaluate the
quality of the estimators.
Based on the same model, Kafadar et al. (1998) examine the variances of the
two derived estimators. Later in Kafadar and Prorok (2003), various methods of
categorizing the screening trial data are studied with the goal of minimizing biasness
in estimation. Then in Kafadar and Prorok (2009), the effects of length-biased
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sampling, i.e. the tendency of a screening to pick up samples with longer preclinical
sojourn times, towards final estimation is investigated.
In addition to all the statistical models developed that evaluate screening
programs, another type of model can be formulated that takes in the various char-
acteristics of the system, such as sojourn time distributions and test sensitivities,
as known inputs and generates an optimal schedule of screening. As we discussed,
such model inputs are often by themselves the products of those screening program
evaluation models, in which case the schedule of screening is treated as fixed and
known.
To this end of optimal screening policy models, Zelen (1993) presents a pi-
oneering model to place any given number of screening epochs over a population’s
lifetime, such that the probability of detecting the disease while preclinical is max-
imized. He adopts his earlier stable disease model, and solves the optimization
problem by considering the first-order conditions. The main result of this work is
the proof that the optimal solution has an equally-spaced structure if and only if the
test sensitivity is one.
Another significant stream of models are due to Parmigiani and Kamlet (1993)
and Parmigiani (1993, 1997). These models are all concerned with the overall cost-
effectiveness of a screening program and seek the best screening schedule for it.
In Parmigiani and Kamlet (1993), the general disease progression model with
competing death risks is first considered. Screening costs are assumed fixed for
each exam and are considered also for the populations that die in any state due to
competing risks. Treatment costs are treated alongside the Quality-Adjusted-Life-
Years (QALY) as functions depending on sojourn times in the healthy and preclinical
states. The model considers a baseline screening schedule and compares the marginal
expected cost against the marginal expected QALY for several proposed screening
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schedules.
Parmigiani (1993) presents a general optimization model to minimize the
overall screening program cost. In the particular case of perfect screening, the author
derives conditions on the input cost functions such that the optimal screening policy
consists either of zero or of infinite number of screenings. In the latter situation,
additional conditions are found to ensure a recursive algorithm to find the optimum.
Indeed, this approach is reminiscent to a classical work in system reliability literature
due to Barlow et al. (1963). Based on first-order optimality conditions, a set of
equations are derived that can generate the screening schedule sequentially once the
first epoch is fixed. In implementation, if either this first screening time is fixed
before or after the optimum, particular faulty patterns will arise in the downstream
schedule calculated. As such, a binary-search algorithm is in place to find the optimal
schedule.
Then in Parmigiani (1997), the author takes a detour approach and approxi-
mates screening schedules by continuous intensity functions. The objective function
remains at minimizing total costs and is also approximated. The optimal solution is
searched from the space of intensity functions, and needs ultimately to be converted
back into a discrete screening schedule. Optimality conditions are studied for this
model.
Later, Lee and Zelen (1998) consider an alternative screening scheme based
on their non-stable disease model. Under this scheme, screening times are placed
in such a way that the prevalence of preclinical samples in the population is always
bounded by a pre-specified upper threshold level. The prevalence function, which
is unobservable, is derived based on assumed sojourn time distributions and test
sensitivity. Once the schedule is derived by the scheme policy, its performance is
measured by the overall probability of preclinical disease detection.
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Parmigiani et al. (2002) study the optimal placement of a single screening
time. Two objective functions are considered, which include the probability of screen-
ing detection and the expected life length for the disease-affected population. De-
pendent sojourn times are considered for the disease-free and preclinical states, and
fallible tests were treated whose specificity depends on the sojourn times. The first-
order conditions for optimality is derived. In a case study conducted on colorectal
cancer, the authors obtain optimal solution by arbitrarily plotting out the objective
function.
Ahern et al. (2011) consider two frameworks for an optimal screening policy.
First, the policy is restricted to be equally spaced, and the authors seek the optimal
number of planned screenings that minimizes the weighted cost between the number
of screenings and the probability of screening detection. A sufficient condition for
a unique optimum is derived, and the authors argue that the practical parameters
for breast cancer will easily satisfy this condition. Secondly, the authors consider
the optimal placement of any given number of screenings and prove the existence
of optimal solution for this framework. Throughout the work the authors treat
the disease-free duration with piece-wise linear densities, assuming an exponential
distribution for the preclinical time, and consider independent and fallible screening
tests.
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3. OPTIMAL SCREENING POLICY MODEL FORMULATION
We adopt the natural history model of Parmigiani et al. (2002) as the frame-
work for our decision making. As shown in Figure 3.1, we consider five states for
the disease under screening. These are the “healthy”, “preclinical” and “clinical”
states as well as two “dead” states which correspond, respectively, to cases due to
the disease and to competing risks. Transitions can occur as an individual progresses
from healthy to preclinical, from preclinical to clinical, and from clinical to dead as
a result of the disease; meanwhile, it is possible for one to die of other causes while
s/he is in any state up to clinical.
Figure 3.1: Disease Natural History Model
Our optimal screening policy model aims at finding the screening schedule
that produces the maximal probability of preclinical disease detection. We model
budget in terms of the total number of screenings allowed in a person’s lifetime and
in practice this can be easily converted to a dollar value. In our model, we confine
our attention to samples that will develop clinical symptoms (before dying of a
competing risk) if not screened. We acknowledge that in practice screening costs are
also incurred for those who die without the disease and are thus actually irrelevant to
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the screening program. We will discuss such implications of program-wide screening
costs in our numerical analysis chapter.
Therefore, we assume that an individual will, with probability one, transit
over three states: healthy, preclinical, and clinical. Let random variables X0 and X1
be the sojourn times, respectively, in the healthy and the preclinical states, and let f
and g be the p.d.f.’s for X0 and X1. Figure 3.2 shows the simple disease progression
model that we consider. Note that all individuals will eventually be “diagnosed”,
either by a screening, or due to clinical symptoms.
Figure 3.2: Scope of Our Optimal Screening Policy Model
We make the following assumptions:
• f is a log-concave function over (a, b) for 0 ≤ a < b ≤ ∞,
• g is independent of f and is supported over (0,∞),
• all screenings are independent and have sensitivity β.
The class of log-concave density functions include a broad range of models
such as all uniform, exponential and normal distributions as well as all Weibull
and Gamma densities with shape parameter greater than one. Many interesting
properties can be found in this class of functions (see Barlow et al. (1963)). In
particular, all log-concave densities have increasing failure rates.
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The other two assumptions are mild and can be found in many other studies
(e.g. Day and Walter (1984), Zelen (1993), Lee and Zelen (1998), Shen and Zelen
(1999), Ahern et al. (2011)).
Now, let D ⊂ Rn := {(τ1, τ2, ..., τn) | 0 < τ1 < τ2 < ... < τn < b} be the set of
all possible screening policies. Note that for each fixed policy, an individual will be
missed detection either if his/her preclinical period covers no screening epoch on the
schedule (see Figure 3.3); or, all the screening(s) performed during the preclinical pe-
riod fail to report the truth. All other scenarios correspond to the event of successful
detection. Figure 3.4 presents a few scenarios of possible successful detections. Note
a detection only happens if at least one of the screenings during X1 was accurate.
Figure 3.3: Examples of Missed Detections
We, therefore, derive our objective function as follows:
14
Figure 3.4: Examples of Potential Successful Detections
Proposition 1 The objective function
P (τ ) = Pr({Preclinical Detection})
= 1−
n∑
i=0
n∑
j=i
βj−i
∫ τi+1
τi
[G(τj+1 − u)−G(τj − u)]f(u)du,
where τ0 = 0 and τn+1 = ∞, β is the false-negative rate for screenings, and where
F/f and G/gare the distribution and density functions for the random sojourn times
X0 and X1, respectively, of an individual in the healthy and preclinical states.
Proof:
We have
P (τ ) := Pr({Preclinical Detection}) = 1− Pr({Missed Detection})
= 1−
n∑
i=0
n∑
j=i
Pr
(
X0 ∈ (τi, τi+1), X0 +X1 ∈ (τj, τj+1),Missed Detection
)
= 1−
n∑
i=0
n∑
j=i
∫ τi+1
τi
Pr
(
X0 ∈ (τi, τi+1), X0 +X1 ∈ (τj, τj+1),
Missed Detection | X0 = u
)
f(u)du
= 1−
n∑
i=0
n∑
j=i
∫ τi+1
τi
Pr
(
X1 ∈ (τj − u ∨ 0, τj+1 − u),
Missed Detection | X0 = u
)
f(u)du
= 1−
n∑
i=0
n∑
j=i
∫ τi+1
τi
βj−i · [G(τj+1 − u)−G(τj − u)]f(u)du
15
[by independence and the number of screenings while in preclinical state]
Note the above expression is regardless of b.

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4. MODEL SOLUTION FOR PERFECT SCREENING CASE
We first consider the partial derivatives of the objective function.
Proposition 2 For each k ∈ {1, 2, · · · , n},
∂
∂τk
P (τ ) =(1− β)
{
f(τk)
[
(1− β)
n−k∑
j=1
βj−1G(τk+j − τk) + βn−k
]
−
k−2∑
i=0
βk−i−1
∫ τi+1
τi
g(τk − u)f(u)du−
∫ τk
τk−1
g(τk − u)f(u)du
}
.
Proof:
For each k ∈ {1, 2, · · · , n} and τ ∈ D, it holds that:
∂
∂τk
P (τ ) =− ∂
∂τk
{
k−2∑
i=0
∫ τi+1
τi
βk−i−1[G(τk − u)−G(τk−1 − u)]f(u)du
+
k−2∑
i=0
∫ τi+1
τi
βk−i[G(τk+1 − u)−G(τk − u)]f(u)du
+
n∑
j=k−1
∫ τk
τk−1
βj−k+1[G(τj+1 − u)−G(τj − u)]f(u)du
+
n∑
j=k
∫ τk+1
τk
βj−k[G(τj+1 − u)−G(τj − u)]f(u)du
}
=− ∂
∂τk
{
(1− β)
k−2∑
i=0
βk−i−1
∫ τi+1
τi
G(τk − u)f(u)du
+ (1− β)
n−k∑
j=0
βj
∫ τk
τk−1
G(τk+j − u)f(u)du
+ (1− β)
n−k∑
j=1
βj−1
∫ τk+1
τk
G(τk+j − u)f(u)du
− (1− β)βn−kF (τk)
}
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=− (1− β)
{
k−2∑
i=0
βk−i−1
∫ τi+1
τi
g(τk − u)f(u)du
− (1− β)
n−k∑
j=1
βj−1G(τk+j − τk)f(τk)
+
∫ τk
τk−1
g(τk − u)f(u)du− βn−kf(τk)
}
=(1− β)
{
f(τk)
[
(1− β)
n−k∑
j=1
βj−1G(τk+j − τk) + βn−k
]
−
k−2∑
i=0
βk−i−1
∫ τi+1
τi
g(τk − u)f(u)du−
∫ τk
τk−1
g(τk − u)f(u)du
}

Our main result is the following.
Theorem 1 If screenings are perfectly sensitive (i.e. β = 0), then there exists a
unique optimal policy σ = {σ1, σ2, · · · , σn}, which is characterized by the following
criterion:

(1)
∫ σ1−σ0
0
f(σ1−s)
f(σ1)
g(s)ds = G(σ2 − σ1)
...
...
(i)
∫ σi−σi−1
0
f(σi−s)
f(σi)
g(s)ds = G(σi+1 − σi)
...
...
(n)
∫ σn−σn−1
0
f(σn−s)
f(σn)
g(s)ds
 =≤
1 (if σn < b)
1 (if σn = b).
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Proof:
If β = 0, the partial derivative for each τk is:
∂
∂τk
P (τ ) = f(τk)G(τk+1 − τk)−
∫ τk
τk−1
g(τk − u)f(u)du
= f(τk)
[
G(τk+1 − τk)−
∫ τk−τk−1
0
f(τk − s)
f(τk)
g(s)ds
]
.
Now notice that for τk over interval (τk−1, τk+1), G(τk+1−τk) strictly decreases
from G(τk+1−τk−1) to 0, and the term
∫ τk−τk−1
0
f(τk−s)
f(τk)
g(s)ds strictly increases from 0
to
∫ τk+1−τk−1
0
f(τk+1−s)
f(τk+1)
g(s)ds. The latter monotonicity holds because for any s ∈ (0, b),
f(τ−s)
f(τ)
is non-decreasing in τ if f is logconcave (see Barlow et al. (1963)). As a result,
for τk−1 < τk < τ ′k < τk+1, we have:
∫ τk−τk−1
0
f(τk − s)
f(τk)
g(s)ds ≤
∫ τk−τk−1
0
f(τ ′k − s)
f(τ ′k)
g(s)ds
<
∫ τk−τk−1
0
f(τ ′k − s)
f(τ ′k)
g(s)ds+
∫ τ ′k−τk−1
τk−τk−1
f(τ ′k − s)
f(τ ′k)
g(s)ds
=
∫ τ ′k−τk−1
0
f(τ ′k − s)
f(τ ′k)
g(s)ds.
Meanwhile, notice f(τk) is positive and continuous over (τk−1, τk+1).
Therefore, we know from the partials that for any chosen policy τ ∈ D, as we
vary each τk, the objective function will always turn from increasing to decreasing
over (τk−1, τk+1), with the only exception that it could possibly never decrease in
τn. As such, the optimal solution must have at least n − 1 zero partials, hence our
criterion.
To show uniqueness, suppose two different solutions τ and ψ both satisfy the
optimal criterion. Let i = min{k : τk 6= ψk} be the first element where the two
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solutions differ, and without loss of generality, assume τi < ψi. We have:
(i)
∫ τi−τi−1
0
f(τi−s)
f(τi)
g(s)ds = G(τi+1 − τi)
...
...
(n− 1)∫ τn−1−τn−2
0
f(τn−1−s)
f(τn−1)
g(s)ds = G(τn − τn−1)
(n)
∫ τn−τn−1
0
f(τn−s)
f(τn)
g(s)ds
 =≤
1 (if τn < b)
1 (if τn = b),
and

(i)′
∫ ψi−ψi−1
0
f(ψi−s)
f(ψi)
g(s)ds = G(ψi+1 − ψi)
...
...
(n− 1)′∫ ψn−1−ψn−2
0
f(ψn−1−s)
f(ψn−1)
g(s)ds = G(ψn − ψn−1)
(n)′
∫ ψn−ψn−1
0
f(ψn−s)
f(ψn)
g(s)ds
 =≤
1 (if ψn < b)
1 (if ψn = b).
Now, sequentially for each k ∈ {i, · · · , n− 1}, it follows that:
(k)⇔ τk+1 − τk = G−1
(∫ τk−τk−1
0
f(τk − s)
f(τk)
g(s)ds
)
< G−1
(∫ ψk−ψk−1
0
f(ψk − s)
f(ψk)
g(s)ds
)
= ψk+1 − ψi ⇔ (k)′,
which gives τk+1 − τk < ψk+1 − ψk and τk+1 < ψk+1.
Therefore, we have τn − τn−1 < ψn − ψn−1 and τn < ψn. But this is a
contradiction, as:
(n)⇔ 1 =
∫ τn−τn−1
0
f(τn − s)
f(τn)
g(s)ds <
∫ ψn−ψn−1
0
f(ψn − s)
f(ψn)
g(s)ds ≤ 1⇔ (n)′.
As a result, a unique solution satisfies the optimality criterion.

20
In fact, for the general case where β > 0, note that:
∂
∂τk
P (τ ) =(1− β)
{
f(τk)
[
(1− β)
n−k∑
j=1
βj−1G(τk+j − τk) + βn−k
]
−
k−2∑
i=0
βk−i−1
∫ τi+1
τi
g(τk − u)f(u)du−
∫ τk
τk−1
g(τk − u)f(u)du
}
=(1− β)f(τk)
{[
(1− β)
n−k∑
j=1
βj−1G(τk+j − τk) + βn−k
]
−
∫ τk−τk−1
0
f(τk − s)
f(τk)
g(s)ds
}
− (1− β)
k−2∑
i=0
βk−i−1
∫ τi+1
τi
g(τk − u)f(u)du,
where the expression in
{}
is strictly decreasing in τk from a positive quantity near
τk−1. However, to guarantee uniqueness of optimal solution, more assumptions are
required about densities f and g in order to leverage the last term.
In the following contents in this chapter, unless otherwise specified we assume
that β = 0.
Now, notice that for any arbitrary τ1 we may specify, the optimality criterion
nicely allows us to calculate {τ2, τ3, · · · , τn} sequentially through its first n− 1 equa-
tions. And finally, the last condition is used to check for optimality of the solution
generated. Consider the following algorithm.
Binary First Epoch Search Algorithm (BFESA)
Step 0: Let L = 0. If b <∞, let U = b; otherwise, let U be a number big enough to
contain σ1, e.g. U = 2F
−1( 1
n
). Let  be an arbitrary small number.
Step 1: Set τ1 =
L+U
2
.
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Step 2: For each k ∈ {2, · · · , n}, calculate τk = τk−1+G−1
( ∫ τk−1−τk−2
0
f(τk−1−s)
f(τk−1)
g(s)ds
)
.
Step 3: If
∫ τk−1−τk−2
0
f(τk−1−s)
f(τk−1)
g(s)ds > 1 for any k ∈ {2, · · · , n}, or if τk ≥ b for any
k ∈ {2, · · · , n − 1} or τn > b, or if
∫ τn−τn−1
0
f(τn−s)
f(τn)
g(s)ds > 1 + , then set
U = τ1 and return to Step 1. Otherwise, if
∫ τn−τn−1
0
f(τn−s)
f(τn)
g(s)ds < 1 − ,
then set L = τ1 and return to Step 1.
Step 4: The algorithm stops and the screening policy {τ1, τ2, · · · , τn} is reported.
We prove that the BFESA finds the optimal solution.
Theorem 2 The BFESA converges to the optimal solution.
Proof:
We first prove that either τ1 is chosen to be too large or too small, there will
be one distinctive signal throughout calculating τ2 through τn to report this.
Specifically, if τ1 > σ1, we have:
τ2 − τ1 = G−1
(∫ τ1
0
f(τ1 − s)
f(τ1)
g(s)ds
)
> G−1
(∫ σ1
0
f(σ1 − s)
f(σ1)
g(s)ds
)
= σ2 − σ1.
Note it is possible to have
∫ τ1
0
f(τ1−s)
f(τ1)
g(s)ds > 1, or that τ2 ≥ b. In either case,
we obtain a signal that our chosen τ1 is larger than σ1.
If τ2 < b, we get τ2 − τ1 > σ2 − σ1 and τ2 > σ2, and we proceed to equation
(2). Now as each equation (k) is applied where k ∈ {2, · · · , n− 1}, we have:
τk+1 − τk = G−1
(∫ τk−τk−1
0
f(τk − s)
f(τk)
g(s)ds
)
> G−1
(∫ σk−σk−1
0
f(σk − s)
f(σk)
g(s)ds
)
= σk+1 − σk,
under which it is possible that
∫ τk−τk−1
0
f(τk−s)
f(τk)
g(s)ds > 1 or τk+1 ≥ b, i.e. signals for
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τ1 > σ1. If not, we get τk+1 − τk > σk+1 − σk and τk+1 > σk.
Now assume we have sequentially applied equations (1) through (n − 1) to
find such {τ2, · · · , τn} thatτk − τk−1 > σk − σk−1 and τk > σk for all k ∈ {2, · · · , n}.
Assume also that τn ≤ b. But from equation (n), we have:
∫ τn−τn−1
0
f(τn − s)
f(τn)
g(s)ds >
∫ σn−σn−1
0
f(σn − s)
f(σn)
g(s)ds = 1,
which again indicates τ1 to be too large.
On the other hand, if τ1 < σ1, then by applying equations (1) through (n−1)
we will obtain such {τ2, · · · , τn} that τk − τk−1 < σk − σk−1 and τk < σk for all
k ∈ {2, · · · , n}. But in this case, equation (n) will give:
∫ τn−τn−1
0
f(τn − s)
f(τn)
g(s)ds <
∫ σn−σn−1
0
f(σn − s)
f(σn)
g(s)ds = 1,
a signal that τ1 < σ1.
In each iteration, notice the BFESA collects a signal and responds accordingly
to cut off half of the search region for σ1. It therefore converges to the optimal
solution.

We next devote some effort to study the structure of the optimal screening
policy. We have the following important result.
Theorem 3 For each τ1 ∈ (0, b), there exists a unique τ ∗(τ1) = {τ ∗2 (τ1), τ ∗3 (τ1), · · · , τ ∗n(τ1)}
that maximizes P (τ1, ·). Further, τ ∗ behaves in such a way that each of its elements
τ ∗k is strictly increasing and concave in τ1 (with the only exception that τ
∗
n could
remain constant once it reaches b).
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Proof:
For fixed τ1 ∈ (0, b) and each k ∈ {2, · · · , n}, note the partial derivative of
P (τ ) with respect to τk can be treated as follows:
∂
∂τk
P (τ ) =f(τk)
[
G(τk+1 − τk)−
∫ τk−τk−1
0
f(τk − s)
f(τk)
g(s)ds
]
=[1− F (τ1)] f(τk)
1− F (τ1)
[
G(τk+1 − τk)−
∫ τk−τk−1
0
f(τk−s)
1−F (τ1)
f(τk)
1−F (τ1)
g(s)ds
]
=[1− F (τ1)]f τ1(τk)
[
G(τk+1 − τk)−
∫ τk−τk−1
0
f τ1(τk − s)
f τ1(τk)
g(s)ds
]
,
where we define
f τ1(s) :=
f(s)
1− F (τ1) for s ∈ (τ1, b)
to be the conditional p.d.f. for random variable X0 given that it is greater than τ1.
As the logarithm of f is concave, it is necessary that f τ1 , which is f by a
scalar, is log-concave also. Therefore, we may view the n− 1 partials as a full set of
derivatives for the problem of n − 1 screenings, which has f τ1 as the p.d.f. for X0
and is scaled by a positive constant. Thus, by Theorem 1 there is a unique policy
{τ ∗2 (τ1), τ ∗3 (τ1), · · · , τ ∗n(τ1)} to maximize P (τ ).
To show monotonicity and concavity of each τ ∗k with respect to τ1, we pick
0 < τ1 < τ
′
1 < b, and let τ = {τ1, τ2, · · · , τn} and τ ′ = {τ ′1, τ ′2, · · · , τ ′n} be the
policies to maximize P (τ1, ·) and P (τ ′1, ·) respectively. Also, let ∆k = τk+1 − τk and
∆′k = τ
′
k+1 − τ ′k for each k ∈ {1, · · · , n− 1}.
We want to show that: (a) ∆′k < ∆k for each k ∈ {1, · · · , n − 1}, and (b)
τ ′k > τk for each k ∈ {2, · · · , n} (except for possibly τn = τ ′n = b). Notice if (a) holds,
then we will have τ ′k−τk = (τ ′1 +
∑k−1
j=1 ∆
′
j)− (τ1 +
∑k−1
j=1 ∆j) = (τ
′
1−τ1)+
∑k−1
j=1(∆
′
j−
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∆j) < τ
′
1− τ1 for each k ∈ {2, · · · , n}. As a result, each τ ∗k is increasing and concave
in τ1, and the theorem is thus proven.
By the optimality criterion from Theorem 1, we have the following:

(2)
∫ τ2−τ1
0
f(τ2−s)
f(τ2)
g(s)ds = G(τ3 − τ2)
...
...
(i)
∫ τi−τi−1
0
f(τi−s)
f(τi)
g(s)ds = G(τi+1 − τi)
...
...
(n)
∫ τn−τn−1
0
f(τn−s)
f(τn)
g(s)ds
 =≤
1 (if τn < b)
1 (if τn = b)

(2)′
∫ τ ′2−τ ′1
0
f(τ ′2−s)
f(τ ′2)
g(s)ds = G(τ ′3 − τ ′2)
...
...
(i)′
∫ τ ′i−τ ′i−1
0
f(τ ′i−s)
f(τ ′i)
g(s)ds = G(τ ′i+1 − τ ′i)
...
...
(n)′
∫ τ ′n−τ ′n−1
0
f(τ ′n−s)
f(τ ′n)
g(s)ds
 =≤
1 (if τ ′n < b)
1 (if τ ′n = b)
We shall prove our claims in the order of ∆′1 < ∆1, τ
′
2 > τ2, ∆
′
2 < ∆2, · · · ,
∆′n−1 < ∆n−1, and b ≥ τ ′n ≥ τn. Consider the following algorithmic arguments:
For claim (a): suppose we have proven up to some k ∈ {1, · · · , n − 1} that
τ ′j > τj ∀j ∈ {1, · · · , k} and ∆′j < ∆j ∀j ∈ {1, · · · , k − 1}. We want to show
∆′k < ∆k.
Assume the claim is NOT true, i.e. ∆′k ≥ ∆k. Let i = k, then:
(*) By assumption, it holds that ∆′i ≥ ∆i and τ ′i+1 > τi+1.
25
If now i = n− 1, we will have:
(n)⇔ 1 =
∫ ∆n−1
0
f(τn − s)
f(τn)
g(s)ds <
∫ ∆′n−1
0
f(τ ′n − s)
f(τ ′n)
g(s)ds ≤ 1⇔ (n)′,
which is a contradiction.
Otherwise, we have:
(i+ 1)⇔ τi+2 − τi+1 = G−1
(∫ ∆i
0
f(τi+1 − s)
f(τi+1)
g(s)ds
)
< G−1
(∫ ∆′i
0
f(τ ′i+1 − s)
f(τ ′i+1)
g(s)ds
)
= τ ′i+2 − τ ′i+1 ⇔ (i+ 1)′,
which is ∆′i+1 > ∆i+1.
Now let i := i+ 1, and go back to step (*). The same arguments will then go
through iteratively until i reaches n− 1, at which point we get a contradiction and
conclude that ∆′k < ∆k.
For claim (b): suppose we have proven up to some k ∈ {1, · · · , n − 1} that
τ ′j > τj and ∆
′
j < ∆j ∀j ∈ {1, · · · , k}. We want to show τ ′k+1 > τk+1 if k < n− 1, or
that b ≥ τ ′n ≥ τn if k = n− 1.
Again assume the claim is NOT true, i.e. τ ′k+1 ≤ τk+1 if k < n− 1 or τ ′n < τn
if k = n− 1. Let i = k, then:
(*) By assumption, it holds that ∆′i < ∆i and τ
′
i+1 ≤ τi+1.
If i = n− 1, then we have:
(n)⇔ 1 ≥
∫ ∆n−1
0
f(τn − s)
f(τn)
g(s)ds >
∫ ∆′n−1
0
f(τ ′n − s)
f(τ ′n)
g(s)ds = 1⇔ (n)′,
which is a contradiction.
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Otherwise, we have:
(i+ 1)⇔ τi+2 − τi+1 = G−1
(∫ ∆i
0
f(τi+1 − s)
f(τi+1)
g(s)ds
)
> G−1
(∫ ∆′i
0
f(τ ′i+1 − s)
f(τ ′i+1)
g(s)ds
)
= τ ′i+2 − τ ′i+1 ⇔ (i+ 1)′,
which is ∆′i+1 < ∆i+1.
Now let i := i+ 1, and go back to step (*). The same arguments will then go
through iteratively until i reaches n− 1, at which point we get a contradiction and
conclude that τ ′k+1 > τk+1.

We have the following corollary.
Corollary 1 Given event {X0 > σ1}, the policy {σ2, σ3, · · · , σn} is the optimal
solution to the (n− 1)-screening problem.
Proof: Clear from proof to Theorem 3.

Practically, Theorem 3 is helpful for people who enter the screening program
late. Indeed, provided a delayed first screening time, we now know that all the
subsequent screenings shall be postponed for better probability of detection. On the
other hand, Corollary 1 verifies that the optimal screening policy is self-consistent.
We have an additional result on the locations of the optimal screening epochs
with respect to the optimal policy from the previous budget level.
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Theorem 4 Let φ = {φ1, φ2, · · · , φn−1} denote the optimal policy for the (n − 1)-
screening problem. Define also that φ0 = 0 and φn = b. Then the optimal n-screening
policy σ is such that all its n screening epochs lie in the intervals created by φ, i.e.
σk ∈ (φk−1, φk) for k ∈ {1, · · · , n− 1}, and φn−1 ≤ σn ≤ φn.
Proof:
To show σk > φk−1 for each k ∈ {1, · · · , n− 1} and σn ≥ φn−1, we may treat
φ as the policy to optimize an n-screening problem, given that the first screening
epoch is at time 0. Since σ1 > φ0, the inequalities follow by Theorem 3.
And to show σk < φk for each k ∈ {1, · · · , n− 1}, notice σ is such that:

(1)
∫ σ1−σ0
0
f(σ1−s)
f(σ1)
g(s)ds = G(σ2 − σ1)
...
...
(i)
∫ σi−σi−1
0
f(σi−s)
f(σi)
g(s)ds = G(σi+1 − σi)
...
...
(n)
∫ σn−σn−1
0
f(σn−s)
f(σn)
g(s)ds
 =≤
1 (if σn < b)
1 (if σn = b)
And φ is such that:

(1)′
∫ φ1−φ0
0
f(φ1−s)
f(φ1)
g(s)ds = G(φ2 − φ1)
...
...
(i)′
∫ φi−φi−1
0
f(φi−s)
f(φi)
g(s)ds = G(φi+1 − φi)
...
...
(n− 1)′∫ φn−1−φn−2
0
f(φn−1−s)
f(φn−1)
g(s)ds
 =≤
1 (if φn−1 < b)
1 (if φn−1 = b)
Recall our proof to Theorem 1. If σ1 ≥ φ1, then for each i ∈ {1, · · · , n− 2},
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we have σi+1 − σi ≥ φi+1 − φi and σi+1 ≥ φi+1. Further, it holds that:
G(σn−σn−1) =
∫ σn−1−σn−2
0
f(σn−1 − s)
f(σn−1)
g(s)ds ≥
∫ φn−1−φn−2
0
f(φn−1 − s)
f(φn−1)
g(s)ds = 1,
therefore, necessarily σn =∞. But now, check that:
lim
σn→∞
∫ σn−σn−1
0
f(σn − s)
f(σn)
g(s)ds >
∫ σn−1−σn−2
0
f(σn−1 − s)
f(σn−1)
g(s)ds = 1,
which is a contradiction by (n) in the optimality criterion. As a result, we have
σ1 < φ1.
Consequently, again by applying the first n − 1 equations in the optimality
criterion, we obtain σi < φi for all i ∈ {1, · · · , n− 1}.

Next, we investigate some models with more specific assumptions. In the
class of logconcave densities, note that the uniform and the exponential models
respectively have a constant and a linear logarithm which are special cases of concave
functions. We have the following result for the case of uniform disease-free duration.
Proposition 3 If X0 ∼ Unif(0, b) for some b > 0, then the optimal screening policy
is equally spaced, i.e., σ = { b
n
, 2b
n
, · · · , (n−1)b
n
, b}, if and only if β = 0.
Proof:
When X0 ∼ Unif(0, b) and β = 0, for each k ∈ {1, 2 · · · , n}, we have:
G(σk+1 − σk) =
∫ σk−σk−1
0
f(σk − s)
f(σk)
g(s)ds
=
∫ σk−σk−1
0
g(s)ds [f =
1
b
]
= G(σk − σk−1).
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Therefore σk − σk−1 = bn for all k ∈ {1, 2, · · · , n}.
Conversely, if β > 0, assume that τ = { b
n
, 2b
n
, · · · , (n−1)b
n
, b} is the optimal
policy. We have:
∂
∂τ1
P (τ ) =(1− β)
{
f(τ1)
[
(1− β)
n−1∑
j=1
βj−1G(τ1+j − τ1) + βn−1
]
−
∫ τ1
0
g(τ1 − u)f(u)du
}
=
1− β
b
[
(1− β)
n−1∑
j=1
βj−1G(τ1+j − τ1) + βn−1 −G(τ1)
]
=
1− β
b
[
(1− β)
n−1∑
j=1
βj−1G(
jb
n
) + βn−1 −G( b
n
)
]
=
1− β
b
{
n−2∑
j=1
βj
[
G
((j + 1)b
n
)
−G(jb
n
)
]
+ βn−1
[
1−G
((n− 1)b
n
)]}
> 0,
which is a contradiction to the assumption that τ is optimal.

Notice, however, that in the single-screening case where:
d
dτ
P (τ) =(1− β)
[
f(τ)−
∫ τ
0
g(τ − u)f(u)du
]
=
1− β
b
[1−G(τ)] > 0 ∀τ ∈ (0, b),
the optimal policy is to wait until time b to screen, regardless of β.
We have yet another interesting result about the structure of optimal policy
for the case of exponential X0 with perfect screenings.
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Proposition 4 If X0 ∼ Exp(λ) for some λ > 0, and β = 0, then the optimal policy
σ is such that σi+1− σi > σi− σi−1 ∀i ∈ {1, · · · , n− 1}, i.e., the screening interval
gets wider as the person gets older.
Proof:
When X0 ∼ Exp(λ) and β = 0, for each k ∈ {1, 2 · · · , n}, we have:
G(σk+1 − σk) =
∫ σk−σk−1
0
f(σk − s)
f(σk)
g(s)ds
=
∫ σk−σk−1
0
e−λ(σk−s)
e−λσk
g(s)ds
=
∫ σk−σk−1
0
eλsg(s)ds
>
∫ σk−σk−1
0
g(s)ds [eλs > 1 ∀s > 0]
= G(σk − σk−1).

We hereby highlight that in the literature, Barlow et al. (1963) and Yang
and Klutke (2000) have shown for various inspection problems with an exponential
system lifetime that the optimal schedules have equal intervals. However, with the
additional preclinical state in our model, and with our particular objective to capture
the disease while in that state, the structure of the optimal solution is different.
Lastly, on the sideline, we prove that all logconcave densities are bounded.
Proposition 5 If f is logconcave over (0, b), where b ≤ ∞, then it is bounded.
Proof:
Since f is continuous, it suffices to show lim
x→0
f(x) and lim
x→b
f(x) are finite. We
will prove for the end of x→ b and the other side will follow in the same way.
31
As logf is concave, (logf)′ decreases over (0, b). There are then two possibil-
ities:
One, there is some x∗ ∈ (0, b) for which (logf)′(x) ≤ 0 ∀x ∈ [x∗, b). In this
case, logf decreases over [x∗, b), and so does f = elogf . As f > 0, lim
x→b
f(x) must be
finite.
Otherwise, if lim
x→b
(logf)′(x) ≥ 0, let x∗ := b
2
. It then holds that (logf)′(x∗) ≥
(logf)′(x) ∀x ∈ [x∗, b), and so logf(x) ≤ logf(x∗) + (x−x∗)(logf)′(x∗) ≤ logf(x∗) +
b
2
(logf)′(x∗), which is a constant. As a result, f = elogf is bounded over [ b
2
, b) and
lim
x→b
f(x) is finite.

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5. SENSITIVITY ANALYSIS
In the previous chapter we have shown that a unique optimal solution exists
for our preclinical disease screening model once the screening sensitivity and the
distribution functions for the healthy and the preclinical durations are specified. In
this chapter, we investigate the effects of changing these model inputs on the optimal
screening policy and its performance.
We solve all our optimization instances by Matlab’s “constrained optimiza-
tion” (fmincon) routine. Indeed, the only constraints involved are those that ensure
the increasing order of screening epochs.
5.1 Effect of Screening Sensitivity
We have proven in Proposition 3 that if the healthy duration X0 follows a uni-
form distribution and if screening sensitivity is one, then the optimal screening policy
is equally spaced. Our first investigation is then the effect of screening sensitivity on
a uniform X0 model.
We assume X0 follows a uniform distribution with a range of 24 years. One
could interpret this with arbitrary starting and ending ages, e.g. from 40 to 64, or
from 50 to 74 years old. In all our numerical results to follow, we assume all X0
densities start at age 40. On the other hand, we assume that the preclinical duration
X1 has an exponential distribution with mean of 3 years. We consider the screening
budget to be from 1 to 24 times in a person’s lifetime. The 24-screening scenario
corresponds to holding an average of one screening per year over the support of X0.
We consider four false-negative rates of screening (β-errors), namely, 0, 0.4,
0.8, and 0.99. The computation time for a typical case across all 24 budget levels is
about 10 seconds on a computer with Intel(R) Core(TM)2 Duo CPUs each running
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at 3.16GHz and with 4.00G RAM.
Figure 5.1 shows the performances of both optimal and equal-interval policies
across budget levels.
Figure 5.1: Effect of β-error on Policy Performances - Uniform X0 Model
As expected, the performance of optimal screening policies decreases as β-
error increases. Meanwhile, Figure 5.1 shows that even with 99% false-negative
screenings, there is no distinctive difference between optimal and equal-interval poli-
cies’ performances.
We then take a closer look at the change of optimal policy itself as we vary β.
In Figure 5.2 we plot the optimal policies for the 12-screening scenario over various
levels of β-error.
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Figure 5.2: Effect of β-error on Optimal Policy Structure - Uniform X0 Model
As shown, as β-error increases, the screening epochs appear postponed in the
optimal policy.
We next investigate the effect of β-error for another model in which there
exists considerable difference between the optimal and equal-interval policies’ per-
formances. We assume that both X0 and X1 follow gamma distributions, with respec-
tive means of 12 and 3 years, and respective variances of 16 and 3. We experiment
with three levels of β-error respectively at 0.2, 0.6, and 0.9. Figure 5.3 plots the
performances of both optimal and equal-interval policies across β-error levels.
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Figure 5.3: Effect of β-error on Policy Performances - Gamma X0 Model
As depicted, by increasing β there is no significant change on the difference
between optimal and equal-interval policies’ performances. This result is consistent
with that of the uniform X0 model.
We further plot the structure of optimal policies for the 12-screening case:
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Figure 5.4: Effect of β-error on Optimal Policy Structure - Gamma X0 Model
As shown in Figure 5.4, as β-error increases the optimal screening epochs tend
to tighten up as opposed to getting postponed as in the uniform X0 case.
5.2 Effect of X0 Distribution
We next consider two alternative log-concave models for X0, namely, the
gamma model and the 2-parameter Weibull model each with shape parameter no
less than one. Since both models comprise two parameters, we may match their first
two moments to that of the uniform distribution we considered in the earlier section.
Table 5.1 summarizes the parameters of our double-moment-matching alter-
native models for X0. Their p.d.f.’s are plotted in Figure 5.5. Note that all three
density functions consist of a mean of 12 years and a variance of 48. We assume
that X1 follows exponential distribution with mean of 3 years and that screening
sensitivity is 0.8 in this section.
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Table 5.1: Parameters for Double-Moment-Matching Models for X0
Model Parameters
Uniform a = 0, b = 24
Gamma k = 3, θ = 4
Weibull λ = 13.4908, k = 1.7915
Figure 5.5: Plot of Double-Moment-Matching p.d.f.’s for X0
The performances of these models are shown in Figures 5.6 and 5.7. A typical
instance with gamma X0 takes about 2 hours to solve, and with Weibull X0 1.5 hours.
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Figure 5.6: Sensitivity Analysis - Double-Moment-Matching Gamma X0
Figure 5.7: Sensitivity Analysis - Double-Moment-Matching Weibull X0
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As shown, for both gamma and Weibull X0 models, the performances of
the optimal policies are slightly worse than in the uniform model. Also, not much
probability of screening-detection will be sacrificed even if we simply apply the equal-
interval policies. These results suggest that when the first two moments are fixed
for X0, the exact density function would not impact the optimal policy performance
greatly.
We next investigate cases where only the mean of X0 is fixed. Specifically, for
each alternative model, we consider two additional values for its variance, namely,
16 and 144. Notice that in both gamma and Weibull families, the only density that
has mean of 12 and variance of 144 is the exponential distribution with rate 1/12,
which is the special case having shape parameter one in each family.
Table 5.2 summarizes the parameters of the three gamma densities we con-
sider. Their p.d.f.’s are plotted in Figure 5.8, and the performances of optimal policies
for the three models are shown in Figure 5.9.
Table 5.2: Parameters for Gamma Densities for X0
Choice Parameters
Uniform k = 9, θ = 4/3 (Mean= 12, Var= 16)
Gamma k = 3, θ = 4 (Mean= 12, Var= 48)
Weibull k = 1, θ = 12 (Mean= 12, Var= 144)
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Figure 5.8: Plot of Gamma p.d.f.’s for X0
Figure 5.9: Sensitivity Analysis - Variance of Gamma X0
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Additionally, Table 5.3 summarizes the parameters of the three Weibull den-
sities we consider. The p.d.f.’s are plotted in Figure 5.10, and the performances of
optimal policies for the three models are shown in Figure 5.11.
Table 5.3: Parameters for Weibull Densities for X0
Choice Parameters
1 λ = 13.3770, k = 3.3035 (Mean= 12, Var= 16)
2 λ = 13.4908, k = 1.7915 (Mean= 12, Var= 48)
3 λ = 12.0000, k = 1.0000 (Mean= 12, Var= 144)
Figure 5.10: Plot of Weibull p.d.f.’s for X0
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Figure 5.11: Sensitivity Analysis - Variance of Weibull X0
As shown in Figures 5.9 and 5.11, the variance of X0 does play a key role
on the optimal policy’s performance. In the 24-screening scenario, the probability of
detection ranges from around 70% to 85% at optimality as variance decreases, for
both gamma and Weibull X0 models.
5.3 Effect of Distribution of X1
We now consider alterative models for X1. We assume that X0 follows an
exponential distribution with mean of 12 years and that screening sensitivity is 0.8
in this section.
We first consider gamma densities for X1. Again, we fix the first moment, at 3
years, and we consider three versions of distribution that respectively have variances
of 3, 9, and 27. Notice the second choice is the exponential distribution.
The parameters considered for the gamma densities for X1 are summarized
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in Table 5.4, and their corresponding p.d.f.’s are plotted in Figure 5.12.
Table 5.4: Parameters for Gamma Densities for X1
Choice Parameters
default a = 1, b = 3
1 a = 3, b = 1
2 a = 1/3, b = 9
Figure 5.12: Plot of Gamma p.d.f.’s for X1
The model outputs are presented in Figure 5.13. The computation time for
a typical instance up to 24 screenings is 1.5 hours.
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Figure 5.13: Sensitivity Analysis - Variance of Gamma X1
As in the case of X0, the performance of optimal policy is sensitive to the
variance of X1. At the 24-screening budget level, the probability of screen-detection
can reach as high as 0.85 when X1 has variance 3, and as low as 0.40 when X1
has variance 27. From Figure 5.12, one would not reject the small variance gamma
density as a realistic representation for a disease. If this is the underlying truth, then
promising screening performance can be achieved at optimality.
We next consider a lognormal model for X1. The parameters considered are
summarized in Table 5.5, and the p.d.f.’s plotted in Figure 5.14.
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Table 5.5: Parameters for Lognormal Densities for X1
Choice Parameters
1 µ = 0.9548, σ = 0.5364 (Mean= 3, Var= 3)
2 µ = 0.7520, σ = 0.8326 (Mean= 3, Var= 9)
3 µ = 0.4055, σ = 1.1774 (Mean= 3, Var= 27)
Figure 5.14: Plot of Lognormal p.d.f.’s for X1
The optimal policy performances are shown in Figure 5.15. A typical case
takes about 1.5 hours to solve.
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Figure 5.15: Sensitivity Analysis - Variance of Lognormal X1
Similar results hold on the strong sensitivity of X1’s variance over the perfor-
mance of optimal policy. In addition, at all three variance levels, the optimal policy
from the lognormal X1 model outperforms that of the gamma X1 model.
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6. A CASE STUDY USING BREAST CANCER DATA
In this chapter, we present the results we obtain as we apply our model to
the screening for breast cancer.
The practice of breast cancer screening started as early as in the 1960s. Several
screening modalities are currently in place to detect initial stage of breast cancers,
including mammogram, clinical breast exam, breast self-exam, and in some cases,
ultrasound and magnetic resonance imaging (MRI). However, the very questions of
when the screening should start and how often it should be conducted have been
debated over the decades.
In the literature, it is often considered that the population progresses into
the preclinical breast cancer stage at a constant rate (see Zelen and Feinleib (1969),
Zelen (1993), Walter and Day (1983), Day and Walter (1984)). Such models are called
“stable disease models”, and they essentially assume that the healthy duration follows
a uniform distribution. Furthermore, based on stable disease models, statistical
works have been done that found the exponential model for X1 to best represent
data collected from the actual screening trials (see Zelen and Feinleib (1969), Walter
and Day (1983)). Thus, we set up our case-study model by assuming uniform and
exponential distributions for the two random times.
We first set up our model by specifying its objective function and by extracting
parameters from the literature for the two density functions and the sensitivity of
screening exams. We then solve the model to optimality and consider its robustness.
We last investigate issues of average number of screenings and the expected lead time
under optimal policies.
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6.1 Model Setup
We first analytically specify the objective function for our case-study model.
This takes away unnecessarily numerical integrations in running the optimization
routine.
Proposition 6 If X0 ∼ Unif (0, b) for some b < ∞ and X1 ∼ Exp(λ) for λ > 0,
then the objective function is
max
τ∈D
1− β
λb
n−1∑
i=0
n∑
j=i+1
βj−i−1
[
e−λ(τj−τi+1) − e−λ(τj−τi)
]
Proof:
max
τ∈D
1−
n∑
i=0
n∑
j=i
βj−i
∫ τi+1
τi
[G(τj+1 − u)−G(τj − u)]f(u)du
= 1−
{ n−1∑
i=0
n−1∑
j=i+1
βj−i
1
b
∫ τi+1
τi
e−λ(τj−u) − e−λ(τj+1−u)du
+
n−1∑
i=0
1
b
∫ τi+1
τi
[1− e−λ(τi+1−u)]du+
n−1∑
i=0
βn−i
1
b
∫ τi+1
τi
e−λ(τn−u)du+
1
b
∫ b
τn
1 du
}
= 1−
{ n−1∑
i=0
n−1∑
j=i+1
βj−i
1
b
(e−λτj − e−λτj+1)
∫ τi+1
τi
eλudu
+
n−1∑
i=0
1
b
[
(τi+1 − τi)− e−λτi+1
∫ τi+1
τi
eλudu
]
+
n−1∑
i=0
βn−i
1
b
e−λτn
∫ τi+1
τi
eλudu
+
1
b
(b− τn)
}
= 1−
{ n−1∑
i=0
n−1∑
j=i+1
βj−i
1
λb
[
e−λ(τj−τi+1) + e−λ(τj+1−τi) − e−λ(τj+1−τi+1) − e−λ(τj−τi)
]
−
n−1∑
i=0
1
λb
[
1− e−λ(τi+1−τi)
]
+
n−1∑
i=0
βn−i
1
λb
[
e−λ(τn−τi+1) − e−λ(τn−τi)
]
+ 1
}
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= 1− 1
λb
n−1∑
i=0
{
(1− β)
n∑
j=i+2
βj−i−1
[
e−λ(τj−τi) − e−λ(τj−τi+1)
]
+(1− β)
[
e−λ(τi+1−τi) − 1
]}
− 1
=
1− β
λb
n−1∑
i=0
n∑
j=i+1
βj−i−1
[
e−λ(τj−τi+1) − e−λ(τj−τi)
]

We parameterize our model as follows. The uniform distribution of X0 is
assumed to have a range of 24 years. We take this number based on U.S. Preventive
Services Task Force’s recommendation that women should be screened between ages
50 and 75. We choose 24 years as the actual range as we can then easily refer to a
collection of periodic policies (e.g. yearly, biennial , 3-yearly and 4-yearly screenings)
which all divide the support exactly. We further assume that the risk of preclinical
breast cancer begins at age 40, according to American Cancer Society. As a result,
we treat random variable X0 with a uniform (40, 64) distribution.
The exponential distribution for X1 is assumed to have mean length of 3
years, and the rate of β-error for screening exams is assumed to be 0.2. We take
these numbers off various works in the literature (see Walter and Day (1983), Shen
and Zelen (1999), Shen and Parmigiani (New York: Springer, 2006)), and from
surveying domain experts.
In Table 6.1, we summarize our choices of distributions and parameters in our
breast cancer screening model.
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Table 6.1: Breast Cancer Screening Model Parameters
Input Distribution/Parameter
r.v. X0 Unif(40, 64)
r.v. X1 Exp(1/3)
β-error 0.2
6.2 Optimal Solution and Its Robustness
In Figure 6.1 we plot the performance of optimal screening polices across
budget levels 3 through 8, which we consider practical. Recall our objective function
is the probability of detection by screening. Recall also that in Figure 5.2 we had
shown for a model with the same setup that the equal-interval policy performs almost
as greatly as optimal.
Figure 6.1: Breast Cancer Model - Optimal Policy Performance
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As shown, with 12 screenings planed, at optimality about 65% preclinical
cases can be found by screening.
Next we investigate the robustness of the above result.
We first consider varying the range of X0 and the mean duration of X1. To
this end, we show a simple yet insightful result for the special case in which screening
is perfectly sensitive. As we know that the optimal policy is equally spaced in this
case, we may derive a closed-form expression for the optimal objective value.
Proposition 7 If X0 ∼ Unif (0, b), X1 ∼ Exp(λ) and β = 0, then the optimal
objective value is P (σ(n)) = n
bλ
(1−e− bλn ), which increases in n and 1/λ, and decreases
in b.
Proof:
If β = 0, then
P (σ(n)) =
n−1∑
i=0
∫ σ(n)i+1
σ
(n)
i
f(s)[1−G(σ(n)i+1 − s)]ds
=
n−1∑
i=0
∫ b
n
(i+1)
b
n
(i)
1
b
e−λ[
b
n
(i+1)−s]ds
=
1
b
n−1∑
i=0
e−
bλ
n
(i+1)
∫ b
n
(i+1)
b
n
(i)
eλsds
=
1
bλ
n−1∑
i=0
e−
bλ
n
(i+1)[e
bλ
n
(i+1) − e bλn i]
=
1
bλ
n−1∑
i=0
(1− e− bλn )
=
n
bλ
(1− e− bλn )
Now, let x = bλ
n
, and consider P (σ(n)) as P (x) = 1−e
−x
x
. Note as x → 0, both
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numerator 1−e−x and denominator x tend to 0; but for all x > 0, (1−e−x)′ = e−x < 1
while x′ = 1. We therefore have P (x) is a decreasing function for positive x.

The above result suggests that the longer the preclinical sojourn time is in
comparison to the disease-free time, the easier it will be for screenings to capture the
disease.
We next consider a few alternative configurations on the distributions of X0
and X1. Specifically, we hold the means of the two random variables respectively
at 12 years and 3 years, and we consider Weibull and gamma models for X0 with a
variance of 16 (original being 48), and also a gamma model for X1 with a variance
of 3 (original being 9). We hold β at 0.2 throughout this investigation.
Additionally, for all alternative models, we consider Quantile-Based Inspec-
tion (QBI) policies as follows: at each budget level n, we schedule the screening
epochs at the 1/(n+ 1) through n/(n+ 1) quantiles of the X0 distribution. The QBI
policies were initially considered in the context of replaceable system inspection by
Yang and Klutke (2000).
We compare the performances of optimal, QBI and EI policies for our four
alternative models and we present the results in Figures 6.2 through 6.5.
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Figure 6.2: Breast Cancer Model Robustness - Gamma X0 and Exponential X1
Figure 6.3: Breast Cancer Model Robustness - Gamma X0 and Gamma X1
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Figure 6.4: Breast Cancer Model Robustness - Weibull X0 and Exponential X1
Figure 6.5: Breast Cancer Model Robustness - Weibull X0 and Gamma X1
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As shown, in all four cases, the EI policies perform much worse than optimal.
We raise our concern about this observation as in practice most screening recom-
mendations are equally-spaced in nature. Although many studies assume a uniform
X0, there has been rather limited empirical evidence to support this treatment. Our
results reveal that when the underlying preclinical incidence is not stable, the EI
policy can act far off the mark.
On the other hand, the QBI policies perform rather closely to optimal in all
four cases. We consider the reason for this as that the QBI in its nature exploits
the information about X0 distribution. In practice, QBI may serve as a good heuris-
tic to compute high-quality screening policies without running the time-consuming
optimization routines.
Furthermore, as we had seen from the previous chapter, when variance is not
so high for either X0 or X1’s underlying distribution, the performance of optimal
policy can be much enhanced. In cases of both small variances on X0 and X1 (see
Figures 6.3 and 6.5), close to 90% probability of detection is achievable with only 12
screenings planned.
6.3 Additional Evaluations
We last study a few additional issues in our disease screening model and we
evaluate these numerically for our breast cancer screening case.
6.3.1 Expected Number of Screenings
First, we note that throughout our analysis, the “screening budget” is defined
as the “maximum number of screenings allowed” in a person’s lifetime. The actual
number of screenings for an individual is indeed a random variable which depends
not only on internal factors such as the disease-free and preclinical sojourn times,
but also external ones like screening sensitivity and the screening policy itself.
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We therefore first derive an expression for the expected number of screenings
for an individual in the disease-affected population.
Proposition 8 For screening policy τ = {τ1, τ2, ..., τn}, and for a disease-affected
population that has f and g respectively as its disease-free and preclinical sojourn
time densities and β as screening sensitivity, the average number of screenings per
person (denote this by “ND”) is:
ND(τ ) =
n∑
i=1
i
{∫ τi+1
τi
G(τi+1−u)f(u)du+(1−β)
i−1∑
j=0
∫ τj+1
τj
[1−G(τi−u)]βi−j−1f(u)du
}
,
where τn+1 :=∞.
Proof:
ND(τ ) =
n∑
i=1
i · Pr
(
Number of Screenings = i
)
=
n∑
i=1
i
{ i−1∑
j=0
∫ τj+1
τj
Pr(Number of Screenings = i | X0 = u)f(u)du
+
∫ τi+1
τi
Pr(Number of Screenings = i | X0 = u)f(u)du
}
=
n∑
i=1
i
{ i−1∑
j=0
∫ τj+1
τj
[1−G(τi − u)]βi−j−1(1− β)f(u)du
[event happens when X1 survives at least τi − u amount of time, first
i− j − 1 screenings are all false-negative, and the (i− j)th screening
is successful]
+
∫ τi+1
τi
G(τi+1 − u)f(u)du
}
[event happens when X1 does not survive till τi]
=
n∑
i=1
i
{∫ τi+1
τi
G(τi+1 − u)f(u)du
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+(1− β)
i−1∑
j=0
∫ τj+1
τj
[1−G(τi − u)]βi−j−1f(u)du
}

The above expression is derived by assigning the right probabilities to each
number of screenings while considering the two sojourn times and the β-errors. We
omit the details as these are similar to our derivation for the probability of screening
detection in Proposition 1.
In particular, under our basic breast cancer model assumptions, we have the
following.
Corollary 2 If X0 ∼ Unif(0, b) and X1 ∼ Exp(λ), then:
ND(τ ) =
n−1∑
i=1
i
b
{
(τi+1 − τi)− 1
λ
[1− e−λ(τi+1−τi)]
+
1− β
λ
i−1∑
j=0
βi−j−1[e−λ(τi−τj+1) − e−λ(τi−τj)]
}
+
n
b
{
(b− τn) + 1− β
λ
n−1∑
j=0
βn−j−1[e−λ(τn−τj+1) − e−λ(τn−τj)]
}
.
Proof:
ND(τ ) =
n−1∑
i=1
i
b
{∫ τi+1
τi
[1− e−λ(τi+1−u)]du+ (1− β)
i−1∑
j=0
βi−j−1
∫ τj+1
τj
e−λ(τi−u)du
}
+
n
b
{∫ b
τn
1du+ (1− β)
n−1∑
j=0
βn−j−1
∫ τj+1
τj
e−λ(τn−u)du
}
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=
n−1∑
i=1
i
b
{
(τi+1 − τi)− e−λτi+1
∫ τi+1
τi
eλudu
+(1− β)
i−1∑
j=0
βi−j−1e−λτi
∫ τj+1
τj
eλudu
}
+
n
b
{
(b− τn) + (1− β)
n−1∑
j=0
βn−j−1e−λτn
∫ τj+1
τj
eλudu
}
=
n−1∑
i=1
i
b
{
(τi+1 − τi)− 1
λ
[1− e−λ(τi+1−τi)]
+
1− β
λ
i−1∑
j=0
βi−j−1[e−λ(τi−τj+1) − e−λ(τi−τj)]
}
+
n
b
{
(b− τn) + 1− β
λ
n−1∑
j=0
βn−j−1[e−λ(τn−τj+1) − e−λ(τn−τj)]
}

Next, we examine the expected number of screenings per person in a popula-
tion that never develops the disease in its lifetime. This measure reflects the impact
of a screening programme to people who are not benefitted yet who follow the same
recommendation to screen.
The following is clear.
Proposition 9 For screening policy τ = {τ1, τ2, ..., τn}, and for a disease-free pop-
ulation with lifetime distribution function H, the average number of screenings per
person (denote this by “NF”) is:
NF (τ ) =
n∑
i=1
i[H(τi+1)−H(τi)],
where H(τn+1) := 1.
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We then apply the above two definitions to data from breast cancer screening.
Specifically, for the disease-affected population, we assume the model with param-
eters in Table 6.1, and for the disease-free population, we take the 2008 American
females life table (National Vital Statistics System (2012)) for its lifetime distribu-
tion. In doing so, we assume that the proportion of disease-affected samples is rather
small in the overall population. We calculate the expected number of screenings for
both populations as the optimal policy is applied at each budget level. The results
are shown in Table 6.2 and plotted in Figure 6.6.
Table 6.2: Expected Number of Screenings under Optimal Policies
Budget Disease-affected Group Disease-free Group
1 0.1 0.9
2 1.6 1.8
3 2.1 2.8
4 2.6 3.7
5 3.1 4.7
6 3.6 5.6
7 4.0 6.6
8 4.5 7.5
9 5.0 8.5
10 5.5 9.4
11 5.9 10.3
12 6.4 11.3
13 6.9 12.2
14 7.4 13.2
15 7.9 14.1
16 8.4 15.1
17 8.8 16.0
18 9.3 16.9
19 9.8 17.9
20 10.3 18.8
21 10.8 19.8
22 11.3 20.7
23 11.8 21.7
24 12.2 22.6
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Figure 6.6: Expected Number of Screenings under Optimal Policies
As depicted, both populations appear to consist of a fairly linear relationship
between screening budget and the average number of screenings their individuals
will experience. For the disease-free population, screening budget is almost identical
to the actual number of screenings. This is because in reality not many women
will die between ages 40 and 64 (our assumed age range for the preclinical breast
cancer incidence) and as a result, almost every woman ends up going on all the
planned screening exams. As for the disease-affected population, the ratio between
expected number of screenings and screening budget is approximately 1 to 2. Recall
an individual may stop screening at any time due to occurrence of clinical symptoms
or due to screen-detection of the disease.
As a result, in evaluating the real benefits of a screening programme, one
needs not only to beware of the very big number of redundant screenings performed
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to people who are never to develop the disease, but also, to the “diluted” number
of screenings even for the relevant group, thanks to the drastic ratio between the
“nominal” screening budget and the “effective” number of screenings per person.
6.3.2 Expected Lead Time
Our last investigation is on the expected lead time of a screening policy for the
disease-affected population. Indeed, the expected lead time (denote this by “ELT”)
has been used in numerous studies as performance measure of screening policies (e.g.
Zelen and Feinleib (1969), Walter and Day (1983), Parmigiani (1993), Shen and Zelen
(1999), Kafadar and Prorok (2009)). We first derive this quantity as follows.
Proposition 10 For screening policy τ = {τ1, τ2, ..., τn}, and for a disease-affected
population with f and g respectively as disease-free and preclinical sojourn time
densities and β as screening sensitivity, the expected lead time is:
ELT (τ ) = (1− β)
n−1∑
i=0
n∑
j=i+1
j∑
k=i+1
βk−i−1
∫ τi+1
τi
∫ τj+1−u
τj−u
(u+ s− τk)g(s)f(u)dsdu.
Proof:
ELT (τ ) =
n−1∑
i=0
∫ τi+1
τi
E[Lead Time | X0 = u]f(u)du
=
n−1∑
i=0
n∑
j=i+1
∫ τi+1
τi
∫ τj+1−u
τj−u
E[Lead Time | X0 = u,X1 = s]g(s)f(u)dsdu
=
n−1∑
i=0
n∑
j=i+1
∫ τi+1
τi
∫ τj+1−u
τj−u
j∑
k=i+1
(1− β)βk−i−1(u+ s− τk)g(s)f(u)dsdu
= (1− β)
n−1∑
i=0
n∑
j=i+1
j∑
k=i+1
βk−i−1
∫ τi+1
τi
∫ τj+1−u
τj−u
(u+ s− τk)g(s)f(u)dsdu.

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In particular, when X1 is exponential and β = 0, we have the following result.
Proposition 11 If X1 ∼ Exp(λ) and β = 0, then ELT (τ ) equals 1λP (τ ) and is
therefore also maximized by σ.
Proof:
ELT (τ ) =
n−1∑
i=0
∫ τi+1
τi
∫ ∞
τi+1−u
(s+ u− τi+1)g(s)dsf(u)du
=
n−1∑
i=0
∫ τi+1
τi
{
(u− τi+1)e−λ(τi+1−u) −
∫ ∞
τi+1−u
s(e−λs)′ds
}
f(u)du
=
1
λ
n−1∑
i=0
∫ τi+1
τi
∫ ∞
τi+1−u
λe−λsdsf(u)du
=
1
λ
n−1∑
i=0
∫ τi+1
τi
e−λ(τi+1−u)f(u)du.
On the other hand,
P (τ ) = 1−
n∑
i=0
∫ τi+1
τi
G(τi+1 − u)f(u)du
=
n−1∑
i=0
∫ τi+1
τi
[1−G(τi+1 − u)]f(u)du
=
n−1∑
i=0
∫ τi+1
τi
e−λ(τi+1−u)f(u)du
= λ · ELT (τ ).

The above result follows from the memoryless property of exponential distri-
bution. Indeed, knowing that the disease is captured by a screening, the lead time,
i.e. the remaining time in the preclinical state, is but a new exponential quantity.
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As lead time is 0 for cases that are missed by screening, the expected lead time is
simply the probability of detection times the mean of the exponential X1. The next
corollary follows.
Corollary 3 If X0 ∼ Unif(0, b), X1 ∼ Exp(λ), and β = 0, then the expected lead
time is maximized by the equally spaced policy σ, and ELT (σ) = n
bλ2
(1− e− bλn ).
Proof: Clear from Propositions 7 and 11.

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7. CONCLUSIONS
In this dissertation, we have studied the problem of how to schedule a se-
quence of screening times over a person’s lifetime in order to maximize the chance
of capturing a disease while preclinical. Our main result is the proof of uni-modality
of the objective function, by which any problem instance in practice is guaranteed
to be solved optimally with a greedy-search algorithm.
In our numerical experiments we have found that the variances of both the
disease-free and the preclinical sojourn times have large impacts on the performance
of the optimal screening policy. The application of our model to breast cancer screen-
ing further reveals that the equally spaced screenings policies can perform far from
optimal, when the preclinical incidence is non-uniform and when the two sojourn
time distributions have small variances. We further found with our breast cancer
screening model that the disease-free population in practice is screened many more
times than the disease-affected population. We argue that without convincing prac-
tical evidence about the underlying disease progression and screening sensitivity, we
should remain alert about the effectiveness of our current guidelines.
We consider several directions of future work valuable. First, from the mod-
elling’s perspective, it will be beneficial to relax the independence assumptions (be-
tween disease-free and preclinical sojourn times, and between screening sensitivity
and preclinical duration at the time of screening), in order to handle more general
cases. We note that such assumptions played a crucial role for our proofs, and we
expect more specific distributions and/or models to be assumed in order to attain
good analytical results.
Also, it may be interesting to model the disease development (e.g. tumor
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growth) in the preclinical state by some stochastic process models as opposed to a
simple sojourn time as in our approach. The challenge to this end is on the one hand
that the model will become much more intricate to handle, while on the other, there
has been rather limited data from practice to validate/parameterize such models.
Thirdly, other optimization criteria may as well be considered. In this work,
we have shown that maximizing the expected lead time is equivalent to maximizing
the probability of detection for our basic breast cancer model. However, this result is
not easily generalized to cases with different distributions for the two sojourn times.
Analytically, it will be more challenging to handle objective functions that comprise
higher orders of integration such as the expected lead time. Additional techniques
must be developed to tackle such harder problems.
Last but not least, in light of the drastic difference on the expected number
of screenings between the disease-free and the disease-affected populations, it will be
of great economic value to consider tailored screening policies for populations with
varying risk factors. Take breast cancer again for example, certain genetic markers
(e.g. BRAC1, BRAC2) are known to distinguish women’s risk profiles significantly.
The question remains on how we can effectively collect data to characterize the
various risk groups and how to communicate any tailored yet distinctive screening
policies to the public.
In short, despite the almost half-century history of quantitative research on
preclinical disease screening, many more significant and interesting results are yet to
be reaped.
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APPENDIX A. MODEL OUTPUTS
Table A.1: Model Outputs - X0 ∼ Unif(40, 64), X1 ∼ Exp(1/3), β = 0
Scr. Perf. Optimal Screening Policies
Bud. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 12% 64.0 - - - - - - - - - - - - - - - - - - - - - - -
2 25% 52.0 64.0 - - - - - - - - - - - - - - - - - - - - - -
3 35% 48.0 56.0 64.0 - - - - - - - - - - - - - - - - - - - - -
4 43% 46.0 52.0 58.0 64.0 - - - - - - - - - - - - - - - - - - - -
5 50% 44.8 49.6 54.4 59.2 64.0 - - - - - - - - - - - - - - - - - - -
6 55% 44.0 48.0 52.0 56.0 60.0 64.0 - - - - - - - - - - - - - - - - - -
7 60% 43.4 46.9 50.3 53.7 57.1 60.6 64.0 - - - - - - - - - - - - - - - - -
8 63% 43.0 46.0 49.0 52.0 55.0 58.0 61.0 64.0 - - - - - - - - - - - - - - - -
9 66% 42.7 45.3 48.0 50.7 53.3 56.0 58.7 61.3 64.0 - - - - - - - - - - - - - - -
10 69% 42.4 44.8 47.2 49.6 52.0 54.4 56.8 59.2 61.6 64.0 - - - - - - - - - - - - - -
11 71% 42.2 44.4 46.5 48.7 50.9 53.1 55.3 57.5 59.6 61.8 64.0 - - - - - - - - - - - - -
12 73% 42.0 44.0 46.0 48.0 50.0 52.0 54.0 56.0 58.0 60.0 62.0 64.0 - - - - - - - - - - - -
13 75% 41.8 43.7 45.5 47.4 49.2 51.1 52.9 54.8 56.6 58.5 60.3 62.2 64.0 - - - - - - - - - - -
14 76% 41.7 43.4 45.1 46.9 48.6 50.3 52.0 53.7 55.4 57.1 58.9 60.6 62.3 64.0 - - - - - - - - - -
15 78% 41.6 43.2 44.8 46.4 48.0 49.6 51.2 52.8 54.4 56.0 57.6 59.2 60.8 62.4 64.0 - - - - - - - - -
16 79% 41.5 43.0 44.5 46.0 47.5 49.0 50.5 52.0 53.5 55.0 56.5 58.0 59.5 61.0 62.5 64.0 - - - - - - - -
17 80% 41.4 42.8 44.2 45.6 47.1 48.5 49.9 51.3 52.7 54.1 55.5 56.9 58.4 59.8 61.2 62.6 64.0 - - - - - - -
18 81% 41.3 42.7 44.0 45.3 46.7 48.0 49.3 50.7 52.0 53.3 54.7 56.0 57.3 58.7 60.0 61.3 62.7 64.0 - - - - - -
19 82% 41.3 42.5 43.8 45.1 46.3 47.6 48.8 50.1 51.4 52.6 53.9 55.2 56.4 57.7 58.9 60.2 61.5 62.7 64.0 - - - - -
20 82% 41.2 42.4 43.6 44.8 46.0 47.2 48.4 49.6 50.8 52.0 53.2 54.4 55.6 56.8 58.0 59.2 60.4 61.6 62.8 64.0 - - - -
21 83% 41.1 42.3 43.4 44.6 45.7 46.9 48.0 49.1 50.3 51.4 52.6 53.7 54.9 56.0 57.1 58.3 59.4 60.6 61.7 62.9 64.0 - - -
22 84% 41.1 42.2 43.3 44.4 45.5 46.5 47.6 48.7 49.8 50.9 52.0 53.1 54.2 55.3 56.4 57.5 58.5 59.6 60.7 61.8 62.9 64.0 - -
23 84% 41.0 42.1 43.1 44.2 45.2 46.3 47.3 48.3 49.4 50.4 51.5 52.5 53.6 54.6 55.7 56.7 57.7 58.8 59.8 60.9 61.9 63.0 64.0 -
24 85% 41.0 42.0 43.0 44.0 45.0 46.0 47.0 48.0 49.0 50.0 51.0 52.0 53.0 54.0 55.0 56.0 57.0 58.0 59.0 60.0 61.0 62.0 63.0 64.0
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Table A.2: Model Outputs - X0 ∼ Unif(40, 64), X1 ∼ Exp(1/3), β = 0.2
Scr. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 10% 10% 64.0 - - - - - - - - - - - - - - - - - - - - - - -
2 20% 20% 52.3 64.0 - - - - - - - - - - - - - - - - - - - - - -
3 28% 28% 48.4 56.2 64.0 - - - - - - - - - - - - - - - - - - - - -
4 35% 35% 46.5 52.3 58.2 64.0 - - - - - - - - - - - - - - - - - - - -
5 41% 41% 45.3 50.0 54.7 59.4 64.0 - - - - - - - - - - - - - - - - - - -
6 46% 46% 44.4 48.4 52.3 56.3 60.2 64.0 - - - - - - - - - - - - - - - - - -
7 50% 50% 43.9 47.2 50.6 54.0 57.4 60.8 64.0 - - - - - - - - - - - - - - - - -
8 54% 54% 43.4 46.4 49.4 52.3 55.3 58.3 61.3 64.0 - - - - - - - - - - - - - - - -
9 57% 57% 43.1 45.7 48.4 51.0 53.7 56.3 59.0 61.6 64.0 - - - - - - - - - - - - - - -
10 60% 60% 42.8 45.2 47.6 49.9 52.3 54.7 57.1 59.5 61.9 64.0 - - - - - - - - - - - - - -
11 62% 62% 42.5 44.7 46.9 49.1 51.2 53.4 55.6 57.8 60.0 62.1 64.0 - - - - - - - - - - - - -
12 64% 65% 42.3 44.3 46.3 48.3 50.3 52.3 54.3 56.3 58.3 60.3 62.3 64.0 - - - - - - - - - - - -
13 66% 66% 42.2 44.0 45.9 47.7 49.6 51.4 53.3 55.1 57.0 58.8 60.6 62.5 64.0 - - - - - - - - - - -
14 68% 68% 42.0 43.7 45.5 47.2 48.9 50.6 52.3 54.1 55.8 57.5 59.2 60.9 62.6 64.0 - - - - - - - - - -
15 70% 70% 41.9 43.5 45.1 46.7 48.3 49.9 51.5 53.1 54.7 56.3 58.0 59.6 61.2 62.8 64.0 - - - - - - - - -
16 71% 71% 41.8 43.3 44.8 46.3 47.8 49.3 50.8 52.3 53.8 55.3 56.9 58.4 59.9 61.4 62.9 64.0 - - - - - - - -
17 72% 72% 41.7 43.1 44.5 45.9 47.4 48.8 50.2 51.6 53.0 54.5 55.9 57.3 58.7 60.1 61.6 63.0 64.0 - - - - - - -
18 73% 74% 41.6 42.9 44.3 45.6 47.0 48.3 49.7 51.0 52.3 53.7 55.0 56.4 57.7 59.0 60.4 61.7 63.1 64.0 - - - - - -
19 75% 75% 41.5 42.8 44.1 45.3 46.6 47.9 49.2 50.4 51.7 53.0 54.2 55.5 56.8 58.1 59.3 60.6 61.9 63.1 64.0 - - - - -
20 76% 76% 41.4 42.7 43.9 45.1 46.3 47.5 48.7 49.9 51.1 52.3 53.5 54.8 56.0 57.2 58.4 59.6 60.8 62.0 63.2 64.0 - - - -
21 76% 77% 41.4 42.5 43.7 44.8 46.0 47.1 48.3 49.5 50.6 51.8 52.9 54.1 55.2 56.4 57.5 58.7 59.8 61.0 62.1 63.3 64.0 - - -
22 77% 77% 41.3 42.4 43.5 44.6 45.7 46.8 47.9 49.0 50.1 51.2 52.3 53.4 54.5 55.6 56.7 57.8 58.9 60.0 61.1 62.2 63.3 64.0 - -
23 78% 78% 41.3 42.3 43.4 44.4 45.5 46.5 47.6 48.6 49.7 50.8 51.8 52.9 53.9 55.0 56.0 57.1 58.1 59.2 60.2 61.3 62.3 63.4 64.0 -
24 79% 79% 41.2 42.2 43.2 44.2 45.3 46.3 47.3 48.3 49.3 50.3 51.3 52.3 53.3 54.4 55.4 56.4 57.4 58.4 59.4 60.4 61.4 62.4 63.5 64.0
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Table A.3: Model Outputs - X0 ∼ Unif(40, 64), X1 ∼ Exp(1/3), β = 0.4
Scr. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 7% 7% 64.0 - - - - - - - - - - - - - - - - - - - - - - -
2 15% 15% 52.8 64.0 - - - - - - - - - - - - - - - - - - - - - -
3 21% 21% 49.0 56.5 64.0 - - - - - - - - - - - - - - - - - - - - -
4 27% 27% 47.1 52.8 58.5 64.0 - - - - - - - - - - - - - - - - - - - -
5 32% 32% 45.9 50.5 55.1 59.7 64.0 - - - - - - - - - - - - - - - - - - -
6 36% 36% 45.0 48.9 52.8 56.6 60.5 64.0 - - - - - - - - - - - - - - - - - -
7 40% 40% 44.4 47.8 51.1 54.4 57.8 61.1 64.0 - - - - - - - - - - - - - - - - -
8 44% 44% 44.0 46.9 49.8 52.8 55.7 58.6 61.6 64.0 - - - - - - - - - - - - - - - -
9 47% 47% 43.6 46.2 48.8 51.5 54.1 56.7 59.3 61.9 64.0 - - - - - - - - - - - - - - -
10 49% 49% 43.3 45.7 48.0 50.4 52.8 55.1 57.5 59.9 62.2 64.0 - - - - - - - - - - - - - -
11 52% 52% 43.0 45.2 47.4 49.5 51.7 53.8 56.0 58.2 60.3 62.5 64.0 - - - - - - - - - - - - -
12 54% 54% 42.8 44.8 46.8 48.8 50.8 52.8 54.8 56.7 58.7 60.7 62.7 64.0 - - - - - - - - - - - -
13 56% 56% 42.6 44.5 46.3 48.2 50.0 51.8 53.7 55.5 57.4 59.2 61.1 62.9 64.0 - - - - - - - - - - -
14 58% 58% 42.5 44.2 45.9 47.6 49.3 51.1 52.8 54.5 56.2 57.9 59.6 61.3 63.1 64.0 - - - - - - - - - -
15 60% 60% 42.3 43.9 45.5 47.1 48.8 50.4 52.0 53.6 55.2 56.8 58.4 60.0 61.6 63.2 64.0 - - - - - - - - -
16 61% 61% 42.2 43.7 45.2 46.7 48.2 49.8 51.3 52.8 54.3 55.8 57.3 58.8 60.3 61.8 63.3 64.0 - - - - - - - -
17 63% 63% 42.1 43.5 44.9 46.4 47.8 49.2 50.6 52.1 53.5 54.9 56.3 57.7 59.2 60.6 62.0 63.4 64.0 - - - - - - -
18 64% 64% 42.0 43.3 44.7 46.0 47.4 48.7 50.1 51.4 52.8 54.1 55.5 56.8 58.2 59.5 60.8 62.2 63.5 64.0 - - - - - -
19 65% 66% 41.9 43.2 44.5 45.7 47.0 48.3 49.6 50.8 52.1 53.4 54.7 56.0 57.2 58.5 59.8 61.1 62.4 63.6 64.0 - - - - -
20 66% 67% 41.8 43.0 44.3 45.5 46.7 47.9 49.1 50.3 51.6 52.8 54.0 55.2 56.4 57.6 58.8 60.1 61.3 62.5 63.7 64.0 - - - -
21 67% 68% 41.7 42.9 44.1 45.2 46.4 47.5 48.7 49.9 51.0 52.2 53.3 54.5 55.7 56.8 58.0 59.1 60.3 61.5 62.6 63.8 64.0 - - -
22 68% 69% 41.7 42.8 43.9 45.0 46.1 47.2 48.3 49.4 50.5 51.7 52.8 53.9 55.0 56.1 57.2 58.3 59.4 60.5 61.6 62.8 63.9 64.0 - -
23 69% 70% 41.6 42.7 43.7 44.8 45.9 46.9 48.0 49.0 50.1 51.2 52.2 53.3 54.4 55.4 56.5 57.5 58.6 59.7 60.7 61.8 62.9 63.9 64.0 -
24 70% 71% 41.5 42.6 43.6 44.6 45.6 46.6 47.7 48.7 49.7 50.7 51.7 52.8 53.8 54.8 55.8 56.8 57.9 58.9 59.9 60.9 61.9 63.0 64.0 64.0
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Table A.4: Model Outputs - X0 ∼ Unif(40, 64), X1 ∼ Exp(1/3), β = 0.8
Scr. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 2% 2% 64.0 - - - - - - - - - - - - - - - - - - - - - - -
2 5% 5% 54.4 64.0 - - - - - - - - - - - - - - - - - - - - - -
3 7% 7% 51.1 57.7 64.0 - - - - - - - - - - - - - - - - - - - - -
4 9% 10% 49.4 54.4 59.4 64.0 - - - - - - - - - - - - - - - - - - - -
5 11% 12% 48.3 52.4 56.5 60.6 64.0 - - - - - - - - - - - - - - - - - - -
6 13% 14% 47.4 50.9 54.4 57.9 61.4 64.0 - - - - - - - - - - - - - - - - - -
7 15% 16% 46.8 49.9 52.9 55.9 59.0 62.0 64.0 - - - - - - - - - - - - - - - - -
8 17% 17% 46.3 49.0 51.7 54.4 57.1 59.8 62.5 64.0 - - - - - - - - - - - - - - - -
9 19% 19% 45.9 48.4 50.8 53.2 55.6 58.0 60.5 62.9 64.0 - - - - - - - - - - - - - - -
10 20% 21% 45.6 47.8 50.0 52.2 54.4 56.6 58.8 61.0 63.2 64.0 - - - - - - - - - - - - - -
11 22% 22% 45.3 47.3 49.3 51.4 53.4 55.4 57.5 59.5 61.5 63.5 64.0 - - - - - - - - - - - - -
12 23% 24% 45.0 46.9 48.8 50.7 52.5 54.4 56.3 58.2 60.0 61.9 63.8 64.0 - - - - - - - - - - - -
13 25% 26% 44.8 46.5 48.3 50.0 51.8 53.5 55.3 57.0 58.8 60.5 62.3 64.0 64.0 - - - - - - - - - - -
14 26% 27% 44.6 46.2 47.8 49.5 51.1 52.7 54.3 56.0 57.6 59.2 60.9 62.5 64.0 64.0 - - - - - - - - - -
15 27% 28% 44.4 45.9 47.4 49.0 50.5 52.0 53.5 55.1 56.6 58.1 59.6 61.2 62.7 64.0 64.0 - - - - - - - - -
16 29% 30% 44.2 45.6 47.1 48.5 49.9 51.4 52.8 54.2 55.7 57.1 58.6 60.0 61.4 62.9 64.0 64.0 - - - - - - - -
17 30% 31% 44.0 45.4 46.8 48.1 49.5 50.8 52.2 53.5 54.9 56.2 57.6 59.0 60.3 61.7 63.0 64.0 64.0 - - - - - - -
18 31% 32% 43.9 45.2 46.5 47.8 49.0 50.3 51.6 52.9 54.2 55.5 56.7 58.0 59.3 60.6 61.9 63.2 64.0 64.0 - - - - - -
19 32% 33% 43.8 45.0 46.2 47.4 48.6 49.9 51.1 52.3 53.5 54.8 56.0 57.2 58.4 59.6 60.9 62.1 63.3 64.0 64.0 - - - - -
20 33% 35% 43.6 44.8 46.0 47.1 48.3 49.5 50.6 51.8 53.0 54.1 55.3 56.4 57.6 58.8 59.9 61.1 62.3 63.4 64.0 64.0 - - - -
21 35% 36% 43.5 44.6 45.8 46.9 48.0 49.1 50.2 51.3 52.4 53.5 54.6 55.8 56.9 58.0 59.1 60.2 61.3 62.4 63.5 64.0 64.0 - - -
22 36% 37% 43.4 44.5 45.6 46.6 47.7 48.7 49.8 50.9 51.9 53.0 54.1 55.1 56.2 57.3 58.3 59.4 60.5 61.5 62.6 63.6 64.0 64.0 - -
23 37% 38% 43.3 44.3 45.4 46.4 47.4 48.4 49.4 50.5 51.5 52.5 53.5 54.6 55.6 56.6 57.6 58.6 59.7 60.7 61.7 62.7 63.7 64.0 64.0 -
24 38% 39% 43.2 44.2 45.2 46.2 47.2 48.1 49.1 50.1 51.1 52.1 53.0 54.0 55.0 56.0 57.0 57.9 58.9 59.9 60.9 61.9 62.9 63.8 64.0 64.0
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Table A.5: Model Outputs - X0 ∼ Unif(40, 64), X1 ∼ Exp(1/3), β = 0.99
Scr. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 0% 0% 64.0 - - - - - - - - - - - - - - - - - - - - - - -
2 0% 0% 52.0 64.0 - - - - - - - - - - - - - - - - - - - - - -
3 0% 0% 55.2 56.5 64.0 - - - - - - - - - - - - - - - - - - - - -
4 0% 0% 54.9 57.8 58.9 64.0 - - - - - - - - - - - - - - - - - - - -
5 1% 1% 54.6 57.0 59.8 60.8 64.0 - - - - - - - - - - - - - - - - - - -
6 1% 1% 54.2 56.4 58.7 61.3 62.3 64.0 - - - - - - - - - - - - - - - - - -
7 1% 1% 53.3 55.0 56.9 59.1 59.1 61.6 64.0 - - - - - - - - - - - - - - - - -
8 1% 1% 53.1 54.8 56.5 58.2 60.4 60.4 62.5 64.0 - - - - - - - - - - - - - - - -
9 1% 1% 52.8 54.4 56.1 57.7 59.3 61.5 61.5 63.3 64.0 - - - - - - - - - - - - - - -
10 1% 1% 52.5 54.0 55.5 56.9 58.4 59.9 61.4 62.3 64.0 64.0 - - - - - - - - - - - - - -
11 1% 1% 52.3 53.7 55.1 56.5 57.9 59.3 60.8 62.4 62.9 64.0 64.0 - - - - - - - - - - - - -
12 1% 1% 52.0 53.3 54.6 55.9 57.2 58.5 59.8 61.2 62.6 63.2 64.0 64.0 - - - - - - - - - - - -
13 1% 2% 51.8 53.0 54.2 55.4 56.7 57.9 59.1 60.3 61.5 62.9 63.8 64.0 64.0 - - - - - - - - - - -
14 2% 2% 51.6 52.7 53.9 55.0 56.1 57.3 58.4 59.6 60.8 62.2 62.4 63.5 64.0 64.0 - - - - - - - - - -
15 2% 2% 51.4 52.4 53.5 54.6 55.7 56.8 57.8 58.9 60.0 61.1 62.5 62.9 64.0 64.0 64.0 - - - - - - - - -
16 2% 2% 51.2 52.2 53.2 54.2 55.2 56.2 57.2 58.2 59.3 60.3 61.3 62.4 62.9 64.0 64.0 64.0 - - - - - - - -
17 2% 2% 51.0 52.0 52.9 53.9 54.9 55.8 56.8 57.8 58.7 59.7 60.7 61.6 62.7 63.4 64.0 64.0 64.0 - - - - - - -
18 2% 2% 50.8 51.8 52.7 53.6 54.5 55.5 56.4 57.3 58.2 59.2 60.1 61.1 62.3 62.5 63.4 64.0 64.0 64.0 - - - - - -
19 2% 2% 50.7 51.6 52.4 53.3 54.2 55.1 56.0 56.8 57.7 58.6 59.5 60.4 61.2 62.1 63.0 63.8 64.0 64.0 64.0 - - - - -
20 2% 2% 50.5 51.4 52.2 53.1 53.9 54.8 55.6 56.5 57.3 58.2 59.0 59.8 60.9 62.0 62.1 62.9 63.7 64.0 64.0 64.0 - - - -
21 2% 3% 50.4 51.2 52.0 52.8 53.6 54.4 55.2 56.0 56.8 57.6 58.4 59.2 60.1 60.9 61.7 62.4 63.2 64.0 64.0 64.0 64.0 - - -
22 2% 3% 50.2 51.0 51.8 52.5 53.3 54.1 54.9 55.6 56.4 57.2 58.0 58.7 59.5 60.2 61.3 61.8 62.5 63.2 64.0 64.0 64.0 64.0 - -
23 3% 3% 50.1 50.9 51.6 52.4 53.1 53.9 54.6 55.4 56.1 56.9 57.6 58.4 59.1 59.9 60.6 61.4 62.3 62.7 63.5 64.0 64.0 64.0 64.0 -
24 3% 3% 50.0 50.8 51.5 52.2 52.9 53.7 54.4 55.1 55.8 56.6 57.3 58.0 58.7 59.5 60.2 61.1 61.9 62.2 62.8 63.5 64.0 64.0 64.0 64.0
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Table A.6: Model Outputs - X0 ∼ 40 +Gamma(9, 4/3), X1 ∼ Gamma(3, 1), β = 0.2
Scr. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 2% 23% 52.7 - - - - - - - - - - - - - - - - - - - - - - -
2 25% 39% 51.1 54.6 - - - - - - - - - - - - - - - - - - - - - -
3 29% 51% 50.2 52.9 55.9 - - - - - - - - - - - - - - - - - - - - -
4 39% 59% 49.5 51.8 54.1 56.9 - - - - - - - - - - - - - - - - - - - -
5 47% 66% 49.0 51.1 53.0 55.1 57.8 - - - - - - - - - - - - - - - - - - -
6 54% 71% 48.6 50.5 52.2 53.9 55.9 58.5 - - - - - - - - - - - - - - - - - -
7 60% 75% 48.2 50.0 51.5 53.1 54.7 56.6 59.2 - - - - - - - - - - - - - - - - -
8 65% 78% 47.9 49.6 51.0 52.4 53.8 55.4 57.3 59.8 - - - - - - - - - - - - - - - -
9 69% 81% 47.7 49.2 50.6 51.8 53.1 54.5 56.0 57.8 60.3 - - - - - - - - - - - - - - -
10 73% 83% 47.4 48.9 50.2 51.4 52.6 53.8 55.1 56.6 58.4 60.8 - - - - - - - - - - - - - -
11 76% 85% 47.2 48.7 49.9 51.0 52.1 53.2 54.4 55.7 57.1 58.8 61.2 - - - - - - - - - - - - -
12 78% 87% 47.0 48.4 49.6 50.6 51.7 52.7 53.8 54.9 56.2 57.6 59.3 61.7 - - - - - - - - - - - -
13 80% 88% 46.9 48.2 49.3 50.3 51.3 52.3 53.2 54.3 55.4 56.6 58.0 59.7 62.1 - - - - - - - - - - -
14 82% 89% 46.7 48.0 49.1 50.0 51.0 51.9 52.8 53.8 54.8 55.8 57.0 58.4 60.1 62.4 - - - - - - - - - -
15 84% 90% 46.6 47.8 48.8 49.8 50.7 51.5 52.4 53.3 54.2 55.2 56.3 57.4 58.8 60.5 62.8 - - - - - - - - -
16 85% 91% 46.5 47.7 48.7 49.5 50.4 51.2 52.0 52.9 53.7 54.6 55.6 56.7 57.8 59.2 60.8 63.1 - - - - - - - -
17 87% 92% 46.3 47.5 48.5 49.3 50.1 50.9 51.7 52.5 53.3 54.2 55.0 56.0 57.0 58.2 59.5 61.1 63.4 - - - - - - -
18 88% 92% 41.4 46.3 47.5 48.5 49.3 50.1 50.9 51.7 52.5 53.3 54.2 55.0 56.0 57.0 58.2 59.5 61.1 63.4 - - - - - -
19 89% 93% 41.3 46.2 47.4 48.3 49.1 49.9 50.7 51.4 52.2 53.0 53.7 54.6 55.4 56.4 57.4 58.5 59.8 61.4 63.7 - - - - -
20 90% 93% 41.2 46.1 47.2 48.1 49.0 49.7 50.4 51.2 51.9 52.6 53.4 54.1 54.9 55.8 56.7 57.7 58.8 60.1 61.7 64.0 - - - -
21 90% 94% 41.2 46.0 47.1 48.0 48.8 49.5 50.2 50.9 51.6 52.3 53.0 53.7 54.5 55.3 56.1 57.0 58.0 59.1 60.4 62.0 64.3 - - -
22 91% 94% 41.1 45.9 47.0 47.9 48.6 49.3 50.0 50.7 51.4 52.0 52.7 53.4 54.1 54.8 55.6 56.4 57.3 58.3 59.4 60.7 62.3 64.5 - -
23 92% 95% 41.1 45.8 46.9 47.7 48.5 49.2 49.8 50.5 51.1 51.8 52.4 53.1 53.7 54.4 55.2 55.9 56.7 57.6 58.6 59.7 61.0 62.5 64.8 -
24 92% 95% 41.0 45.7 46.8 47.6 48.3 49.0 49.7 50.3 50.9 51.5 52.2 52.8 53.4 54.1 54.8 55.5 56.2 57.0 57.9 58.9 60.0 61.2 62.8 65.0
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Table A.7: Model Outputs - X0 ∼ 40 +Gamma(9, 4/3), X1 ∼ Gamma(3, 1), β = 0.6
Scr. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 1% 12% 52.7 - - - - - - - - - - - - - - - - - - - - - - -
2 12% 21% 51.5 54.1 - - - - - - - - - - - - - - - - - - - - - -
3 15% 28% 50.8 52.8 55.0 - - - - - - - - - - - - - - - - - - - - -
4 20% 34% 50.3 52.0 53.7 55.7 - - - - - - - - - - - - - - - - - - - -
5 24% 40% 49.9 51.4 52.8 54.4 56.3 - - - - - - - - - - - - - - - - - - -
6 28% 44% 49.5 50.9 52.2 53.5 54.9 56.8 - - - - - - - - - - - - - - - - - -
7 32% 48% 49.3 50.6 51.7 52.9 54.1 55.5 57.2 - - - - - - - - - - - - - - - - -
8 36% 52% 49.0 50.2 51.3 52.4 53.4 54.6 55.9 57.6 - - - - - - - - - - - - - - - -
9 39% 55% 48.8 50.0 51.0 52.0 52.9 53.9 55.0 56.3 58.0 - - - - - - - - - - - - - - -
10 42% 58% 48.6 49.7 50.7 51.6 52.5 53.4 54.4 55.4 56.7 58.4 - - - - - - - - - - - - - -
11 45% 61% 48.4 49.5 50.4 51.3 52.1 53.0 53.8 54.8 55.8 57.0 58.7 - - - - - - - - - - - - -
12 48% 63% 48.3 49.3 50.2 51.0 51.8 52.6 53.4 54.2 55.1 56.1 57.4 59.0 - - - - - - - - - - - -
13 50% 65% 48.1 49.1 50.0 50.7 51.5 52.2 53.0 53.8 54.6 55.5 56.5 57.7 59.3 - - - - - - - - - - -
14 53% 67% 48.0 49.0 49.8 50.5 51.2 51.9 52.6 53.4 54.1 54.9 55.8 56.8 57.9 59.5 - - - - - - - - - -
15 55% 69% 47.9 48.8 49.6 50.3 51.0 51.7 52.3 53.0 53.7 54.4 55.2 56.1 57.1 58.2 59.8 - - - - - - - - -
16 57% 71% 47.8 48.7 49.4 50.1 50.8 51.4 52.1 52.7 53.4 54.0 54.8 55.5 56.4 57.3 58.5 60.0 - - - - - - - -
17 59% 71% 41.4 47.8 48.7 49.4 50.1 50.8 51.4 52.1 52.7 53.4 54.0 54.8 55.5 56.4 57.3 58.5 60.0 - - - - - - -
18 61% 72% 41.3 47.6 48.5 49.3 49.9 50.6 51.2 51.8 52.4 53.0 53.7 54.3 55.0 55.8 56.6 57.6 58.7 60.2 - - - - - -
19 62% 74% 41.3 47.5 48.4 49.1 49.8 50.4 51.0 51.6 52.2 52.8 53.4 54.0 54.6 55.3 56.1 56.9 57.8 58.9 60.5 - - - - -
20 64% 75% 41.2 47.4 48.3 49.0 49.6 50.2 50.8 51.4 51.9 52.5 53.1 53.7 54.3 54.9 55.6 56.3 57.1 58.0 59.2 60.7 - - - -
21 66% 76% 41.2 47.3 48.2 48.9 49.5 50.1 50.6 51.2 51.7 52.3 52.8 53.4 53.9 54.5 55.2 55.8 56.6 57.4 58.3 59.4 60.9 - - -
22 67% 77% 41.1 47.3 48.1 48.7 49.3 49.9 50.5 51.0 51.5 52.0 52.6 53.1 53.6 54.2 54.8 55.4 56.1 56.8 57.6 58.5 59.6 61.1 - -
23 68% 78% 41.1 47.2 48.0 48.6 49.2 49.8 50.3 50.8 51.3 51.8 52.3 52.8 53.4 53.9 54.5 55.0 55.6 56.3 57.0 57.8 58.7 59.8 61.3 -
24 70% 79% 41.0 47.1 47.9 48.5 49.1 49.6 50.2 50.7 51.1 51.6 52.1 52.6 53.1 53.6 54.1 54.7 55.3 55.9 56.5 57.2 58.0 58.9 60.0 61.4
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Table A.8: Model Outputs - X0 ∼ 40 +Gamma(9, 4/3), X1 ∼ Gamma(3, 1), β = 0.9
Scr. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 0% 3% 52.7 - - - - - - - - - - - - - - - - - - - - - - -
2 3% 6% 52.2 53.2 - - - - - - - - - - - - - - - - - - - - - -
3 4% 8% 51.8 52.7 53.7 - - - - - - - - - - - - - - - - - - - - -
4 5% 10% 51.5 52.3 53.1 54.0 - - - - - - - - - - - - - - - - - - - -
5 6% 12% 51.3 52.0 52.7 53.5 54.3 - - - - - - - - - - - - - - - - - - -
6 7% 15% 51.0 51.7 52.4 53.1 53.8 54.6 - - - - - - - - - - - - - - - - - -
7 9% 16% 50.9 51.5 52.1 52.7 53.4 54.1 54.9 - - - - - - - - - - - - - - - - -
8 10% 18% 50.7 51.3 51.8 52.4 53.0 53.7 54.4 55.1 - - - - - - - - - - - - - - - -
9 11% 20% 50.5 51.1 51.6 52.2 52.7 53.3 53.9 54.6 55.3 - - - - - - - - - - - - - - -
10 12% 22% 50.4 50.9 51.4 52.0 52.5 53.0 53.6 54.2 54.8 55.5 - - - - - - - - - - - - - -
11 13% 23% 50.3 50.8 51.3 51.8 52.3 52.8 53.3 53.8 54.4 55.0 55.6 - - - - - - - - - - - - -
12 14% 25% 50.2 50.6 51.1 51.6 52.1 52.5 53.0 53.5 54.0 54.6 55.2 55.8 - - - - - - - - - - - -
13 15% 27% 50.1 50.5 51.0 51.4 51.9 52.3 52.8 53.2 53.7 54.2 54.7 55.3 56.0 - - - - - - - - - - -
14 16% 27% 41.7 50.1 50.5 51.0 51.4 51.9 52.3 52.8 53.2 53.7 54.2 54.7 55.3 56.0 - - - - - - - - - -
15 17% 28% 41.6 50.0 50.4 50.8 51.3 51.7 52.1 52.6 53.0 53.4 53.9 54.4 54.9 55.5 56.1 - - - - - - - - -
16 18% 29% 41.5 49.9 50.3 50.7 51.1 51.6 52.0 52.4 52.8 53.2 53.6 54.1 54.6 55.1 55.7 56.3 - - - - - - - -
17 19% 31% 41.4 49.8 50.2 50.6 51.0 51.4 51.8 52.2 52.6 53.0 53.4 53.8 54.3 54.7 55.2 55.8 56.4 - - - - - - -
18 20% 32% 41.4 49.7 50.1 50.5 50.9 51.3 51.7 52.0 52.4 52.8 53.2 53.6 54.0 54.4 54.9 55.4 55.9 56.5 - - - - - -
19 21% 33% 41.3 49.6 50.0 50.4 50.8 51.2 51.5 51.9 52.3 52.6 53.0 53.4 53.7 54.2 54.6 55.0 55.5 56.1 56.7 - - - - -
20 22% 35% 41.2 49.5 49.9 50.3 50.7 51.0 51.4 51.8 52.1 52.5 52.8 53.2 53.5 53.9 54.3 54.7 55.2 55.7 56.2 56.8 - - - -
21 23% 36% 41.2 49.4 49.8 50.2 50.6 50.9 51.3 51.6 52.0 52.3 52.6 53.0 53.3 53.7 54.1 54.5 54.9 55.3 55.8 56.3 56.9 - - -
22 24% 37% 41.1 49.4 49.8 50.1 50.5 50.8 51.2 51.5 51.8 52.2 52.5 52.8 53.2 53.5 53.9 54.2 54.6 55.0 55.5 55.9 56.5 57.0 - -
23 25% 38% 41.1 49.3 49.7 50.0 50.4 50.7 51.1 51.4 51.7 52.0 52.3 52.7 53.0 53.3 53.7 54.0 54.4 54.7 55.1 55.6 56.1 56.6 57.1 -
24 25% 39% 41.0 49.2 49.6 50.0 50.3 50.6 51.0 51.3 51.6 51.9 52.2 52.5 52.8 53.1 53.5 53.8 54.1 54.5 54.9 55.3 55.7 56.2 56.7 57.2
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Table A.9: Model Outputs - X0 ∼ 40 +Gamma(9, 4/3), X1 ∼ Exp(1/3), β = 0.2
Scr. Perf. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. QBI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 4% 19% 21% 53.2 - - - - - - - - - - - - - - - - - - - - - - -
2 23% 32% 33% 51.4 55.1 - - - - - - - - - - - - - - - - - - - - - -
3 28% 41% 43% 50.4 53.1 56.3 - - - - - - - - - - - - - - - - - - - - -
4 35% 47% 49% 49.7 51.9 54.2 57.2 - - - - - - - - - - - - - - - - - - - -
5 41% 53% 54% 49.2 51.1 53.0 55.1 58.0 - - - - - - - - - - - - - - - - - - -
6 46% 57% 59% 48.8 50.5 52.1 53.8 55.8 58.6 - - - - - - - - - - - - - - - - - -
7 51% 60% 62% 48.4 50.0 51.5 52.9 54.5 56.4 59.2 - - - - - - - - - - - - - - - - -
8 54% 63% 65% 48.1 49.6 51.0 52.2 53.6 55.1 57.0 59.6 - - - - - - - - - - - - - - - -
9 57% 66% 68% 47.9 49.3 50.5 51.7 52.9 54.2 55.6 57.4 60.1 - - - - - - - - - - - - - - -
10 60% 68% 70% 47.7 49.0 50.2 51.2 52.3 53.4 54.7 56.1 57.9 60.4 - - - - - - - - - - - - - -
11 62% 70% 72% 47.5 48.8 49.8 50.9 51.8 52.9 53.9 55.1 56.5 58.3 60.8 - - - - - - - - - - - - -
12 65% 71% 73% 47.3 48.5 49.6 50.5 51.4 52.4 53.3 54.4 55.5 56.9 58.6 61.1 - - - - - - - - - - - -
13 66% 73% 75% 47.2 48.3 49.3 50.2 51.1 51.9 52.8 53.8 54.8 55.9 57.2 58.9 61.4 - - - - - - - - - - -
14 68% 74% 76% 47.0 48.2 49.1 50.0 50.8 51.6 52.4 53.2 54.1 55.1 56.2 57.6 59.2 61.7 - - - - - - - - - -
15 70% 75% 77% 46.9 48.0 48.9 49.7 50.5 51.3 52.0 52.8 53.6 54.5 55.5 56.6 57.9 59.5 62.0 - - - - - - - - -
16 71% 76% 78% 46.8 47.9 48.7 49.5 50.3 51.0 51.7 52.4 53.2 54.0 54.8 55.8 56.9 58.1 59.8 62.2 - - - - - - - -
17 72% 77% 78% 41.4 46.8 47.9 48.7 49.5 50.3 51.0 51.7 52.4 53.2 54.0 54.8 55.8 56.9 58.1 59.8 62.2 - - - - - - -
18 74% 78% 79% 41.4 46.7 47.7 48.6 49.3 50.0 50.7 51.4 52.1 52.8 53.5 54.3 55.1 56.1 57.1 58.4 60.0 62.5 - - - - - -
19 75% 79% 80% 41.3 46.6 47.6 48.4 49.1 49.8 50.5 51.1 51.8 52.4 53.1 53.8 54.6 55.4 56.3 57.4 58.6 60.3 62.7 - - - - -
20 76% 80% 81% 41.2 46.5 47.5 48.3 49.0 49.6 50.3 50.9 51.5 52.1 52.8 53.4 54.1 54.9 55.7 56.6 57.6 58.9 60.5 62.9 - - - -
21 76% 81% 82% 41.2 46.4 47.4 48.1 48.8 49.5 50.1 50.7 51.3 51.8 52.4 53.1 53.7 54.4 55.1 55.9 56.8 57.9 59.1 60.7 63.1 - - -
22 77% 81% 82% 41.1 46.3 47.3 48.0 48.7 49.3 49.9 50.5 51.0 51.6 52.2 52.7 53.4 54.0 54.7 55.4 56.2 57.1 58.1 59.3 60.9 63.3 - -
23 78% 82% 83% 41.0 46.2 47.2 47.9 48.6 49.2 49.7 50.3 50.8 51.4 51.9 52.5 53.0 53.6 54.2 54.9 55.6 56.4 57.3 58.3 59.5 61.1 63.4 -
24 79% 82% 84% 41.0 46.1 47.1 47.8 48.4 49.0 49.6 50.1 50.6 51.1 51.7 52.2 52.7 53.3 53.9 54.5 55.1 55.8 56.6 57.5 58.5 59.7 61.3 63.6
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Table A.10: Model Outputs - X0 ∼ 40 +Gamma(3, 4), X1 ∼ Exp(1/3), β = 0.2
Scr. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 5% 14% 51.2 - - - - - - - - - - - - - - - - - - - - - - -
2 19% 25% 49.1 54.0 - - - - - - - - - - - - - - - - - - - - - -
3 27% 32% 47.9 51.5 56.0 - - - - - - - - - - - - - - - - - - - - -
4 34% 39% 47.1 50.1 53.3 57.5 - - - - - - - - - - - - - - - - - - - -
5 39% 44% 46.5 49.1 51.8 54.8 58.8 - - - - - - - - - - - - - - - - - - -
6 44% 48% 46.1 48.4 50.7 53.1 56.0 60.0 - - - - - - - - - - - - - - - - - -
7 48% 52% 45.7 47.8 49.8 51.9 54.2 57.0 60.9 - - - - - - - - - - - - - - - - -
8 51% 55% 45.4 47.4 49.2 51.0 53.0 55.3 58.0 61.8 - - - - - - - - - - - - - - - -
9 54% 57% 45.1 47.0 48.6 50.3 52.1 54.0 56.1 58.8 62.6 - - - - - - - - - - - - - - -
10 57% 60% 44.9 46.6 48.2 49.7 51.3 53.0 54.8 57.0 59.6 63.4 - - - - - - - - - - - - - -
11 59% 62% 44.7 46.3 47.8 49.2 50.6 52.2 53.8 55.6 57.7 60.3 64.0 - - - - - - - - - - - - -
12 61% 64% 44.5 46.1 47.5 48.8 50.1 51.5 52.9 54.5 56.3 58.4 61.0 64.7 - - - - - - - - - - - -
13 63% 65% 44.3 45.8 47.1 48.4 49.6 50.9 52.2 53.7 55.2 57.0 59.0 61.6 65.3 - - - - - - - - - - -
14 64% 67% 44.2 45.6 46.9 48.1 49.2 50.4 51.6 52.9 54.3 55.8 57.6 59.6 62.1 65.8 - - - - - - - - - -
15 66% 68% 44.1 45.4 46.6 47.8 48.9 50.0 51.1 52.3 53.6 54.9 56.4 58.1 60.2 62.7 66.3 - - - - - - - - -
16 67% 70% 43.9 45.3 46.4 47.5 48.5 49.6 50.7 51.8 52.9 54.2 55.5 57.0 58.7 60.7 63.2 66.8 - - - - - - - -
17 68% 71% 43.8 45.1 46.2 47.3 48.3 49.2 50.3 51.3 52.4 53.5 54.7 56.0 57.5 59.2 61.2 63.7 67.3 - - - - - - -
18 69% 72% 43.7 45.0 46.0 47.0 48.0 48.9 49.9 50.9 51.9 52.9 54.0 55.2 56.6 58.0 59.7 61.6 64.1 67.7 - - - - - -
19 70% 73% 43.6 44.9 45.9 46.8 47.8 48.7 49.6 50.5 51.4 52.4 53.5 54.6 55.7 57.0 58.5 60.1 62.1 64.6 68.1 - - - - -
20 71% 74% 43.6 44.7 45.7 46.6 47.5 48.4 49.3 50.1 51.0 52.0 52.9 54.0 55.0 56.2 57.5 58.9 60.6 62.5 65.0 68.6 - - - -
21 72% 75% 43.5 44.6 45.6 46.5 47.3 48.2 49.0 49.8 50.7 51.6 52.5 53.4 54.4 55.5 56.7 57.9 59.3 61.0 62.9 65.4 68.9 - - -
22 73% 76% 43.4 44.5 45.5 46.3 47.1 47.9 48.7 49.5 50.4 51.2 52.0 52.9 53.9 54.9 55.9 57.1 58.3 59.7 61.4 63.3 65.7 69.3 - -
23 74% 76% 43.3 44.4 45.3 46.2 47.0 47.7 48.5 49.3 50.1 50.9 51.7 52.5 53.4 54.3 55.3 56.3 57.5 58.7 60.1 61.7 63.7 66.1 69.7 -
24 74% 77% 43.3 44.3 45.2 46.0 46.8 47.6 48.3 49.0 49.8 50.5 51.3 52.1 52.9 53.8 54.7 55.7 56.7 57.9 59.1 60.5 62.1 64.0 66.5 70.0
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Table A.11: Model Outputs - X0 ∼ 40 + Exp(1/12), X1 ∼ Exp(1/3), β = 0.2
Scr. Perf. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. QBI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 4% 12% 13% 45.5 - - - - - - - - - - - - - - - - - - - - - - -
2 13% 20% 22% 44.0 49.1 - - - - - - - - - - - - - - - - - - - - - -
3 21% 27% 28% 43.3 46.9 51.9 - - - - - - - - - - - - - - - - - - - - -
4 28% 33% 34% 42.8 45.7 49.2 54.3 - - - - - - - - - - - - - - - - - - - -
5 34% 38% 39% 42.5 44.9 47.8 51.3 56.3 - - - - - - - - - - - - - - - - - - -
6 39% 42% 42% 42.2 44.3 46.7 49.6 53.2 58.2 - - - - - - - - - - - - - - - - - -
7 43% 45% 46% 42.0 43.9 46.0 48.4 51.3 54.9 59.9 - - - - - - - - - - - - - - - - -
8 46% 48% 49% 41.8 43.5 45.4 47.5 50.0 52.8 56.4 61.4 - - - - - - - - - - - - - - - -
9 49% 51% 51% 41.7 43.3 45.0 46.9 49.0 51.4 54.3 57.8 62.8 - - - - - - - - - - - - - - -
10 51% 53% 54% 41.6 43.0 44.6 46.3 48.2 50.3 52.7 55.6 59.2 64.2 - - - - - - - - - - - - - -
11 54% 55% 56% 41.5 42.8 44.3 45.8 47.5 49.4 51.5 53.9 56.8 60.4 65.4 - - - - - - - - - - - - -
12 56% 57% 58% 41.4 42.7 44.0 45.4 47.0 48.7 50.6 52.7 55.1 58.0 61.5 66.6 - - - - - - - - - - - -
13 57% 59% 59% 41.3 42.5 43.8 45.1 46.5 48.1 49.8 51.7 53.8 56.2 59.1 62.6 67.6 - - - - - - - - - - -
14 59% 60% 61% 41.3 42.4 43.5 44.8 46.1 47.6 49.1 50.8 52.7 54.8 57.2 60.1 63.7 68.7 - - - - - - - - - -
15 60% 62% 62% 41.2 42.3 43.4 44.5 45.8 47.1 48.6 50.1 51.8 53.7 55.8 58.2 61.1 64.7 69.7 - - - - - - - - -
16 61% 63% 64% 41.1 42.1 43.2 44.3 45.5 46.7 48.1 49.5 51.1 52.8 54.6 56.8 59.2 62.0 65.6 70.6 - - - - - - - -
17 63% 64% 65% 41.1 42.0 43.0 44.1 45.2 46.4 47.6 49.0 50.4 52.0 53.7 55.5 57.7 60.1 62.9 66.5 71.5 - - - - - - -
18 64% 65% 66% 41.1 42.0 42.9 43.9 45.0 46.1 47.2 48.5 49.8 51.3 52.8 54.5 56.4 58.5 60.9 63.8 67.4 72.4 - - - - - -
19 65% 66% 67% 41.0 41.9 42.8 43.7 44.7 45.8 46.9 48.1 49.3 50.7 52.1 53.6 55.4 57.2 59.3 61.8 64.6 68.2 73.2 - - - - -
20 65% 67% 68% 41.0 41.8 42.7 43.6 44.5 45.5 46.6 47.7 48.9 50.1 51.5 52.9 54.4 56.1 58.0 60.1 62.6 65.4 69.0 74.0 - - - -
21 66% 68% 69% 40.9 41.7 42.6 43.4 44.4 45.3 46.3 47.4 48.5 49.6 50.9 52.2 53.7 55.2 56.9 58.8 60.9 63.3 66.2 69.8 74.8 - - -
22 67% 69% 70% 40.9 41.7 42.5 43.3 44.2 45.1 46.0 47.0 48.1 49.2 50.4 51.6 53.0 54.4 56.0 57.7 59.5 61.7 64.1 66.9 70.5 75.5 - -
23 68% 70% 71% 40.9 41.6 42.4 43.2 44.0 44.9 45.8 46.8 47.8 48.8 49.9 51.1 52.3 53.7 55.1 56.7 58.4 60.3 62.4 64.8 67.7 71.2 76.2 -
24 68% 71% 72% 40.8 41.6 42.3 43.1 43.9 44.7 45.6 46.5 47.5 48.4 49.5 50.6 51.8 53.0 54.4 55.8 57.4 59.1 60.9 63.1 65.5 68.3 71.9 76.9
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Table A.12: Model Outputs - X0 ∼ 40 +Weibull(13.3770, 3.3035)(mean = 12, var = 16), X1 ∼ Exp(1/3), β = 0.2
Scr. Perf. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. QBI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 3% 17% 20% 54.3 - - - - - - - - - - - - - - - - - - - - - - -
2 21% 30% 32% 52.2 56.0 - - - - - - - - - - - - - - - - - - - - - -
3 28% 39% 41% 50.9 53.9 57.0 - - - - - - - - - - - - - - - - - - - - -
4 36% 46% 48% 50.0 52.5 54.9 57.8 - - - - - - - - - - - - - - - - - - - -
5 42% 51% 54% 49.3 51.6 53.6 55.7 58.3 - - - - - - - - - - - - - - - - - - -
6 47% 55% 58% 48.7 50.8 52.6 54.4 56.3 58.8 - - - - - - - - - - - - - - - - - -
7 51% 59% 61% 48.2 50.2 51.8 53.4 55.0 56.8 59.2 - - - - - - - - - - - - - - - - -
8 54% 62% 64% 47.8 49.7 51.2 52.6 54.0 55.5 57.2 59.5 - - - - - - - - - - - - - - - -
9 58% 65% 67% 47.5 49.3 50.7 52.0 53.2 54.5 55.9 57.6 59.8 - - - - - - - - - - - - - - -
10 60% 67% 69% 47.2 48.9 50.2 51.4 52.6 53.8 55.0 56.3 57.9 60.1 - - - - - - - - - - - - - -
11 63% 69% 71% 46.9 48.6 49.8 51.0 52.1 53.1 54.2 55.4 56.6 58.2 60.3 - - - - - - - - - - - - -
12 65% 70% 73% 46.7 48.3 49.5 50.6 51.6 52.6 53.6 54.6 55.7 56.9 58.4 60.6 - - - - - - - - - - - -
13 67% 72% 74% 46.5 48.0 49.2 50.2 51.2 52.1 53.0 54.0 55.0 56.0 57.2 58.7 60.8 - - - - - - - - - - -
14 69% 73% 76% 46.3 47.8 48.9 49.9 50.8 51.7 52.6 53.4 54.3 55.3 56.3 57.5 58.9 60.9 - - - - - - - - - -
15 70% 75% 77% 46.1 47.5 48.7 49.6 50.5 51.3 52.2 53.0 53.8 54.7 55.6 56.5 57.7 59.1 61.1 - - - - - - - - -
16 72% 76% 78% 46.0 47.3 48.4 49.4 50.2 51.0 51.8 52.6 53.3 54.1 54.9 55.8 56.8 57.9 59.3 61.3 - - - - - - - -
17 73% 77% 79% 45.8 47.2 48.2 49.1 49.9 50.7 51.5 52.2 52.9 53.7 54.4 55.2 56.1 57.0 58.1 59.4 61.4 - - - - - - -
18 74% 78% 80% 45.7 47.0 48.0 48.9 49.7 50.4 51.2 51.9 52.5 53.2 53.9 54.7 55.4 56.3 57.2 58.3 59.6 61.5 - - - - - -
19 75% 79% 81% 45.5 46.8 47.8 48.7 49.5 50.2 50.9 51.6 52.2 52.9 53.5 54.2 54.9 55.7 56.5 57.4 58.4 59.8 61.7 - - - - -
20 76% 79% 81% 45.4 46.7 47.7 48.5 49.2 50.0 50.6 51.3 51.9 52.5 53.2 53.8 54.5 55.1 55.9 56.7 57.6 58.6 59.9 61.8 - - - -
21 77% 80% 82% 45.3 46.5 47.5 48.3 49.1 49.7 50.4 51.0 51.6 52.2 52.8 53.4 54.1 54.7 55.4 56.1 56.8 57.7 58.7 60.0 61.9 - - -
22 78% 81% 83% 45.2 46.4 47.3 48.1 48.9 49.5 50.2 50.8 51.4 51.9 52.5 53.1 53.7 54.3 54.9 55.6 56.3 57.0 57.9 58.9 60.2 62.0 - -
23 79% 81% 83% 45.1 46.3 47.2 48.0 48.7 49.3 50.0 50.5 51.1 51.7 52.2 52.8 53.3 53.9 54.5 55.1 55.7 56.4 57.2 58.0 59.0 60.3 62.1 -
24 79% 82% 84% 45.0 46.2 47.1 47.8 48.5 49.2 49.8 50.3 50.9 51.4 52.0 52.5 53.0 53.6 54.1 54.7 55.3 55.9 56.6 57.3 58.2 59.1 60.4 62.2
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Table A.13: Model Outputs - X0 ∼ 40 +Weibull(13.4908, 1.7915)(mean = 12, var = 48), X1 ∼ Exp(1/3), β = 0.2
Scr. Perf. Perf. Optimal Screening Policies
Bud. EI Pol. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 5% 13% 51.8 - - - - - - - - - - - - - - - - - - - - - - -
2 18% 23% 49.3 54.7 - - - - - - - - - - - - - - - - - - - - - -
3 27% 31% 47.9 52.0 56.8 - - - - - - - - - - - - - - - - - - - - -
4 33% 37% 46.9 50.4 53.9 58.3 - - - - - - - - - - - - - - - - - - - -
5 39% 42% 46.2 49.2 52.2 55.4 59.6 - - - - - - - - - - - - - - - - - - -
6 44% 46% 45.7 48.4 50.9 53.6 56.6 60.7 - - - - - - - - - - - - - - - - - -
7 48% 50% 45.2 47.7 50.0 52.3 54.8 57.7 61.6 - - - - - - - - - - - - - - - - -
8 51% 53% 44.9 47.2 49.2 51.3 53.4 55.8 58.6 62.4 - - - - - - - - - - - - - - - -
9 54% 56% 44.6 46.7 48.6 50.5 52.4 54.4 56.7 59.4 63.2 - - - - - - - - - - - - - - -
10 57% 59% 44.3 46.3 48.1 49.8 51.5 53.3 55.3 57.5 60.2 63.9 - - - - - - - - - - - - - -
11 59% 61% 44.1 46.0 47.6 49.2 50.8 52.4 54.2 56.1 58.2 60.8 64.5 - - - - - - - - - - - - -
12 61% 63% 43.9 45.7 47.2 48.7 50.2 51.7 53.3 54.9 56.8 58.9 61.4 65.0 - - - - - - - - - - - -
13 63% 64% 43.7 45.4 46.9 48.3 49.7 51.1 52.5 54.0 55.6 57.4 59.5 62.0 65.6 - - - - - - - - - - -
14 64% 66% 43.5 45.2 46.6 47.9 49.2 50.5 51.8 53.2 54.7 56.3 58.0 60.0 62.5 66.0 - - - - - - - - - -
15 66% 68% 43.4 44.9 46.3 47.6 48.8 50.0 51.3 52.5 53.9 55.3 56.8 58.6 60.5 63.0 66.5 - - - - - - - - -
16 67% 69% 43.3 44.7 46.0 47.3 48.4 49.6 50.8 52.0 53.2 54.5 55.9 57.4 59.1 61.0 63.5 66.9 - - - - - - - -
17 68% 70% 43.1 44.6 45.8 47.0 48.1 49.2 50.3 51.4 52.6 53.8 55.0 56.4 57.9 59.5 61.5 63.9 67.3 - - - - - - -
18 69% 71% 43.0 44.4 45.6 46.7 47.8 48.9 49.9 51.0 52.1 53.2 54.3 55.6 56.9 58.4 60.0 61.9 64.3 67.7 - - - - - -
19 70% 72% 42.9 44.3 45.4 46.5 47.5 48.5 49.5 50.5 51.6 52.6 53.7 54.9 56.1 57.4 58.8 60.4 62.3 64.7 68.0 - - - - -
20 71% 73% 42.8 44.1 45.2 46.3 47.3 48.2 49.2 50.2 51.1 52.1 53.2 54.2 55.3 56.5 57.8 59.2 60.8 62.7 65.0 68.4 - - - -
21 72% 74% 42.8 44.0 45.1 46.1 47.0 48.0 48.9 49.8 50.7 51.7 52.7 53.7 54.7 55.8 57.0 58.2 59.6 61.2 63.1 65.4 68.7 - - -
22 73% 75% 42.7 43.9 44.9 45.9 46.8 47.7 48.6 49.5 50.4 51.3 52.2 53.1 54.1 55.1 56.2 57.4 58.6 60.0 61.6 63.4 65.7 69.0 - -
23 74% 76% 42.6 43.8 44.8 45.7 46.6 47.5 48.4 49.2 50.1 50.9 51.8 52.7 53.6 54.6 55.6 56.6 57.8 59.0 60.4 61.9 63.7 66.0 69.3 -
24 74% 77% 42.5 43.7 44.7 45.6 46.4 47.3 48.1 48.9 49.8 50.6 51.4 52.3 53.1 54.0 55.0 56.0 57.0 58.1 59.4 60.7 62.2 64.0 66.3 69.6
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Table A.14: Model Outputs - X0 ∼ 40 + Exp(1/12), X1 ∼ Gamma(3, 1), β = 0.2
Scr. Perf. Optimal Screening Policies
Bud. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 15% 44.4 - - - - - - - - - - - - - - - - - - - - - - -
2 25% 43.5 47.6 - - - - - - - - - - - - - - - - - - - - - -
3 34% 43.1 46.2 50.3 - - - - - - - - - - - - - - - - - - - - -
4 41% 42.7 45.4 48.6 52.7 - - - - - - - - - - - - - - - - - - - -
5 46% 42.5 44.8 47.5 50.7 54.8 - - - - - - - - - - - - - - - - - - -
6 51% 42.3 44.4 46.8 49.4 52.6 56.7 - - - - - - - - - - - - - - - - - -
7 55% 42.1 44.1 46.2 48.5 51.2 54.4 58.5 - - - - - - - - - - - - - - - - -
8 59% 42.0 43.8 45.7 47.8 50.2 52.9 56.1 60.1 - - - - - - - - - - - - - - - -
9 62% 41.9 43.5 45.3 47.3 49.4 51.7 54.4 57.6 61.7 - - - - - - - - - - - - - - -
10 65% 41.8 43.3 45.0 46.8 48.7 50.8 53.2 55.9 59.1 63.1 - - - - - - - - - - - - - -
11 67% 41.7 43.2 44.7 46.4 48.2 50.1 52.2 54.6 57.3 60.4 64.5 - - - - - - - - - - - - -
12 69% 41.6 43.0 44.5 46.0 47.7 49.5 51.4 53.5 55.9 58.6 61.8 65.8 - - - - - - - - - - - -
13 71% 41.6 42.9 44.3 45.7 47.3 48.9 50.7 52.7 54.8 57.1 59.8 63.0 67.1 - - - - - - - - - - -
14 73% 41.5 42.8 44.1 45.5 46.9 48.5 50.1 51.9 53.9 56.0 58.3 61.0 64.2 68.3 - - - - - - - - - -
15 75% 41.5 42.6 43.9 45.2 46.6 48.1 49.6 51.3 53.1 55.0 57.1 59.5 62.2 65.4 69.4 - - - - - - - - -
16 76% 41.4 42.5 43.8 45.0 46.3 47.7 49.2 50.7 52.4 54.2 56.1 58.2 60.6 63.3 66.5 70.5 - - - - - - - -
17 77% 41.4 42.5 43.6 44.8 46.1 47.4 48.8 50.2 51.8 53.5 55.2 57.2 59.3 61.7 64.3 67.5 71.6 - - - - - - -
18 79% 41.3 42.4 43.5 44.6 45.8 47.1 48.4 49.8 51.3 52.8 54.5 56.3 58.2 60.3 62.7 65.4 68.6 72.6 - - - - - -
19 80% 41.3 42.3 43.4 44.5 45.6 46.8 48.1 49.4 50.8 52.3 53.8 55.5 57.3 59.2 61.3 63.7 66.4 69.6 73.6 - - - - -
20 81% 41.2 42.2 43.3 44.3 45.4 46.6 47.8 49.1 50.4 51.8 53.2 54.8 56.4 58.2 60.2 62.3 64.6 67.3 70.5 74.6 - - - -
21 82% 41.2 42.2 43.2 44.2 45.3 46.4 47.5 48.7 50.0 51.3 52.7 54.2 55.7 57.4 59.2 61.1 63.2 65.6 68.3 71.4 75.5 - - -
22 83% 41.2 42.1 43.1 44.1 45.1 46.2 47.3 48.4 49.6 50.9 52.2 53.6 55.1 56.6 58.3 60.1 62.0 64.1 66.5 69.2 72.4 76.4 - -
23 83% 41.1 42.0 43.0 43.9 44.9 46.0 47.0 48.2 49.3 50.5 51.8 53.1 54.5 56.0 57.5 59.2 61.0 62.9 65.0 67.4 70.1 73.2 77.3 -
24 84% 41.1 42.0 42.9 43.8 44.8 45.8 46.8 47.9 49.0 50.2 51.4 52.6 54.0 55.3 56.8 58.4 60.0 61.8 63.7 65.9 68.2 70.9 74.1 78.2
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Table A.15: Model Outputs - X0 ∼ 40 + Exp(1/12), X1 ∼ Gamma(1/3, 9), β = 0.2
Scr. Perf. Optimal Screening Policies
Bud. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 10% 47.4 - - - - - - - - - - - - - - - - - - - - - - -
2 16% 44.9 51.6 - - - - - - - - - - - - - - - - - - - - - -
3 21% 43.8 48.1 54.8 - - - - - - - - - - - - - - - - - - - - -
4 25% 43.1 46.4 50.7 57.3 - - - - - - - - - - - - - - - - - - - -
5 28% 42.6 45.3 48.5 52.9 59.5 - - - - - - - - - - - - - - - - - - -
6 31% 42.3 44.5 47.2 50.4 54.8 61.4 - - - - - - - - - - - - - - - - - -
7 33% 42.0 43.9 46.2 48.8 52.1 56.4 63.1 - - - - - - - - - - - - - - - - -
8 35% 41.8 43.5 45.5 47.7 50.3 53.6 57.9 64.6 - - - - - - - - - - - - - - - -
9 37% 41.6 43.2 44.9 46.8 49.1 51.7 55.0 59.3 66.0 - - - - - - - - - - - - - - -
10 38% 41.5 42.9 44.4 46.1 48.1 50.3 53.0 56.2 60.6 67.2 - - - - - - - - - - - - - -
11 40% 41.4 42.7 44.1 45.6 47.3 49.2 51.5 54.1 57.4 61.7 68.4 - - - - - - - - - - - - -
12 41% 41.3 42.5 43.7 45.1 46.7 48.4 50.3 52.5 55.2 58.5 62.8 69.4 - - - - - - - - - - - -
13 42% 41.2 42.3 43.5 44.7 46.1 47.7 49.4 51.3 53.5 56.2 59.5 63.8 70.4 - - - - - - - - - - -
14 43% 41.1 42.1 43.2 44.4 45.7 47.1 48.6 50.3 52.3 54.5 57.1 60.4 64.7 71.4 - - - - - - - - - -
15 44% 41.1 42.0 43.0 44.1 45.3 46.6 48.0 49.5 51.2 53.1 55.4 58.0 61.3 65.6 72.3 - - - - - - - - -
16 45% 41.0 41.9 42.9 43.9 45.0 46.1 47.4 48.8 50.3 52.0 54.0 56.2 58.8 62.1 66.4 73.1 - - - - - - - -
17 46% 41.0 41.8 42.7 43.7 44.7 45.8 46.9 48.2 49.6 51.1 52.8 54.8 57.0 59.7 62.9 67.3 73.9 - - - - - - -
18 47% 40.9 41.7 42.6 43.5 44.4 45.4 46.5 47.7 49.0 50.4 51.9 53.6 55.5 57.8 60.4 63.7 68.0 74.7 - - - - - -
19 47% 40.9 41.6 42.4 43.3 44.2 45.1 46.1 47.2 48.4 49.7 51.1 52.6 54.3 56.3 58.5 61.1 64.4 68.8 75.4 - - - - -
20 48% 40.8 41.6 42.3 43.1 44.0 44.9 45.8 46.8 47.9 49.1 50.4 51.8 53.3 55.0 56.9 59.2 61.8 65.1 69.4 76.1 - - - -
21 49% 40.8 41.5 42.2 43.0 43.8 44.6 45.5 46.5 47.5 48.6 49.8 51.0 52.4 54.0 55.7 57.6 59.8 62.5 65.8 70.1 76.7 - - -
22 50% 40.8 41.4 42.1 42.8 43.6 44.4 45.3 46.2 47.1 48.1 49.2 50.4 51.7 53.1 54.6 56.3 58.2 60.5 63.1 66.4 70.7 77.4 - -
23 50% 40.7 41.4 42.0 42.7 43.5 44.2 45.0 45.9 46.8 47.7 48.7 49.8 51.0 52.3 53.7 55.2 56.9 58.8 61.1 63.7 67.0 71.3 78.0 -
24 51% 40.7 41.3 42.0 42.6 43.3 44.0 44.8 45.6 46.5 47.4 48.3 49.3 50.4 51.6 52.9 54.3 55.8 57.5 59.4 61.7 64.3 67.6 71.9 78.6
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Table A.16: Model Outputs - X0 ∼ 40 + Exp(1/12), X1 ∼ Lognormal(0.9548, 0.5364)(mean = 3, var = 3), β = 0.2
Scr. Perf. Optimal Screening Policies
Bud. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 14% 44.2 - - - - - - - - - - - - - - - - - - - - - - -
2 25% 43.4 47.3 - - - - - - - - - - - - - - - - - - - - - -
3 34% 42.9 46.0 49.9 - - - - - - - - - - - - - - - - - - - - -
4 41% 42.6 45.2 48.3 52.2 - - - - - - - - - - - - - - - - - - - -
5 47% 42.4 44.7 47.3 50.4 54.3 - - - - - - - - - - - - - - - - - - -
6 52% 42.2 44.3 46.6 49.2 52.3 56.2 - - - - - - - - - - - - - - - - - -
7 56% 42.1 44.0 46.1 48.4 51.0 54.0 57.9 - - - - - - - - - - - - - - - - -
8 60% 42.0 43.7 45.7 47.7 50.0 52.6 55.7 59.6 - - - - - - - - - - - - - - - -
9 63% 41.9 43.5 45.3 47.2 49.3 51.6 54.2 57.3 61.2 - - - - - - - - - - - - - - -
10 66% 41.8 43.3 45.0 46.8 48.7 50.8 53.1 55.7 58.7 62.6 - - - - - - - - - - - - - -
11 68% 41.7 43.2 44.7 46.4 48.2 50.1 52.2 54.5 57.1 60.1 64.0 - - - - - - - - - - - - -
12 71% 41.7 43.0 44.5 46.1 47.7 49.5 51.4 53.5 55.8 58.4 61.5 65.4 - - - - - - - - - - - -
13 73% 41.6 42.9 44.3 45.8 47.4 49.0 50.8 52.7 54.8 57.1 59.7 62.7 66.6 - - - - - - - - - - -
14 75% 41.5 42.8 44.1 45.5 47.0 48.6 50.2 52.0 53.9 56.0 58.3 60.9 64.0 67.9 - - - - - - - - - -
15 76% 41.5 42.7 44.0 45.3 46.7 48.2 49.8 51.4 53.2 55.1 57.2 59.5 62.1 65.1 69.0 - - - - - - - - -
16 78% 41.5 42.6 43.8 45.1 46.5 47.9 49.3 50.9 52.5 54.3 56.2 58.3 60.6 63.2 66.3 70.2 - - - - - - - -
17 79% 41.4 42.5 43.7 44.9 46.2 47.5 48.9 50.4 52.0 53.6 55.4 57.3 59.4 61.7 64.3 67.4 71.3 - - - - - - -
18 80% 41.4 42.4 43.6 44.8 46.0 47.3 48.6 50.0 51.5 53.0 54.7 56.5 58.4 60.5 62.8 65.4 68.4 72.3 - - - - - -
19 81% 41.3 42.4 43.5 44.6 45.8 47.0 48.3 49.6 51.0 52.5 54.1 55.7 57.5 59.4 61.5 63.8 66.4 69.5 73.4 - - - - -
20 82% 41.3 42.3 43.4 44.5 45.6 46.8 48.0 49.3 50.6 52.0 53.5 55.1 56.7 58.5 60.4 62.5 64.8 67.4 70.4 74.4 - - - -
21 83% 41.3 42.2 43.3 44.3 45.4 46.6 47.8 49.0 50.3 51.6 53.0 54.5 56.0 57.7 59.5 61.4 63.5 65.8 68.4 71.4 75.3 - - -
22 84% 41.3 42.2 43.2 44.2 45.3 46.4 47.5 48.7 49.9 51.2 52.5 53.9 55.4 57.0 58.6 60.4 62.3 64.4 66.7 69.3 72.4 76.3 - -
23 85% 41.2 42.1 43.1 44.1 45.1 46.2 47.3 48.4 49.6 50.8 52.1 53.4 54.8 56.3 57.9 59.5 61.3 63.2 65.3 67.6 70.2 73.3 77.2 -
24 86% 41.2 42.1 43.0 44.0 45.0 46.0 47.1 48.2 49.3 50.5 51.7 53.0 54.3 55.7 57.2 58.8 60.4 62.2 64.1 66.2 68.5 71.1 74.2 78.1
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Table A.17: Model Outputs - X0 ∼ 40 + Exp(1/12), X1 ∼ Lognormal(0.7520, 0.8326)(mean = 3, var = 9), β = 0.2
Scr. Perf. Optimal Screening Policies
Bud. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 13% 44.9 - - - - - - - - - - - - - - - - - - - - - - -
2 22% 43.6 48.0 - - - - - - - - - - - - - - - - - - - - - -
3 30% 42.9 46.1 50.6 - - - - - - - - - - - - - - - - - - - - -
4 36% 42.5 45.1 48.3 52.8 - - - - - - - - - - - - - - - - - - - -
5 41% 42.3 44.5 47.1 50.3 54.7 - - - - - - - - - - - - - - - - - - -
6 45% 42.1 44.0 46.2 48.8 52.0 56.5 - - - - - - - - - - - - - - - - - -
7 49% 41.9 43.7 45.6 47.8 50.4 53.6 58.1 - - - - - - - - - - - - - - - - -
8 52% 41.8 43.4 45.1 47.1 49.3 51.9 55.1 59.6 - - - - - - - - - - - - - - - -
9 55% 41.6 43.1 44.8 46.5 48.5 50.7 53.3 56.5 60.9 - - - - - - - - - - - - - - -
10 58% 41.5 42.9 44.4 46.1 47.8 49.8 52.0 54.6 57.8 62.2 - - - - - - - - - - - - - -
11 60% 41.5 42.8 44.2 45.7 47.3 49.1 51.0 53.3 55.8 59.0 63.5 - - - - - - - - - - - - -
12 63% 41.4 42.6 43.9 45.3 46.8 48.5 50.2 52.2 54.4 57.0 60.2 64.6 - - - - - - - - - - - -
13 65% 41.3 42.5 43.7 45.0 46.4 47.9 49.6 51.3 53.3 55.5 58.1 61.3 65.7 - - - - - - - - - - -
14 66% 41.3 42.4 43.6 44.8 46.1 47.5 49.0 50.6 52.4 54.4 56.6 59.2 62.4 66.8 - - - - - - - - - -
15 68% 41.2 42.3 43.4 44.6 45.8 47.1 48.5 50.0 51.6 53.4 55.4 57.6 60.2 63.4 67.8 - - - - - - - - -
16 70% 41.2 42.2 43.3 44.4 45.5 46.8 48.1 49.5 51.0 52.6 54.4 56.3 58.6 61.2 64.4 68.8 - - - - - - - -
17 71% 41.1 42.1 43.1 44.2 45.3 46.5 47.7 49.0 50.4 51.9 53.5 55.3 57.3 59.5 62.1 65.3 69.7 - - - - - - -
18 72% 41.1 42.0 43.0 44.0 45.1 46.2 47.4 48.6 49.9 51.3 52.8 54.4 56.2 58.2 60.4 63.0 66.2 70.6 - - - - - -
19 73% 41.1 42.0 42.9 43.9 44.9 46.0 47.1 48.3 49.5 50.8 52.2 53.7 55.3 57.1 59.1 61.3 63.9 67.1 71.5 - - - - -
20 75% 41.0 41.9 42.8 43.8 44.7 45.8 46.8 47.9 49.1 50.3 51.6 53.0 54.5 56.2 57.9 59.9 62.1 64.7 67.9 72.3 - - - -
21 76% 41.0 41.8 42.7 43.6 44.6 45.5 46.6 47.6 48.7 49.9 51.2 52.5 53.9 55.4 57.0 58.7 60.7 62.9 65.5 68.7 73.2 - - -
22 77% 41.0 41.8 42.6 43.5 44.4 45.4 46.3 47.4 48.4 49.5 50.7 51.9 53.3 54.7 56.1 57.8 59.5 61.5 63.7 66.3 69.5 73.9 - -
23 78% 41.0 41.7 42.6 43.4 44.3 45.2 46.1 47.1 48.1 49.2 50.3 51.5 52.7 54.0 55.4 56.9 58.5 60.3 62.3 64.5 67.1 70.3 74.7 -
24 78% 40.9 41.7 42.5 43.3 44.2 45.0 45.9 46.9 47.9 48.9 49.9 51.1 52.2 53.5 54.8 56.2 57.7 59.3 61.1 63.0 65.2 67.8 71.0 75.5
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Table A.18: Model Outputs - X0 ∼ 40 + Exp(1/12), X1 ∼ Lognormal(0.4055, 1.1774)(mean = 3, var = 27), β = 0.2
Scr. Perf. Optimal Screening Policies
Bud. Opt. Pol. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
1 11% 45.6 - - - - - - - - - - - - - - - - - - - - - - -
2 18% 43.8 48.8 - - - - - - - - - - - - - - - - - - - - - -
3 24% 43.0 46.3 51.3 - - - - - - - - - - - - - - - - - - - - -
4 29% 42.5 45.1 48.5 53.5 - - - - - - - - - - - - - - - - - - - -
5 34% 42.1 44.3 46.9 50.3 55.3 - - - - - - - - - - - - - - - - - - -
6 37% 41.9 43.8 46.0 48.6 51.9 56.9 - - - - - - - - - - - - - - - - - -
7 41% 41.7 43.4 45.3 47.4 50.0 53.4 58.4 - - - - - - - - - - - - - - - - -
8 44% 41.6 43.1 44.7 46.6 48.8 51.4 54.7 59.8 - - - - - - - - - - - - - - - -
9 46% 41.5 42.8 44.3 46.0 47.8 50.0 52.6 56.0 61.0 - - - - - - - - - - - - - - -
10 48% 41.4 42.6 44.0 45.5 47.1 49.0 51.2 53.8 57.1 62.2 - - - - - - - - - - - - - -
11 51% 41.3 42.4 43.7 45.1 46.6 48.2 50.1 52.3 54.9 58.2 63.2 - - - - - - - - - - - - -
12 53% 41.2 42.3 43.5 44.7 46.1 47.6 49.2 51.1 53.3 55.9 59.2 64.3 - - - - - - - - - - - -
13 54% 41.1 42.2 43.3 44.4 45.7 47.0 48.5 50.2 52.1 54.2 56.8 60.2 65.2 - - - - - - - - - - -
14 56% 41.1 42.1 43.1 44.2 45.3 46.6 48.0 49.5 51.1 53.0 55.2 57.8 61.1 66.1 - - - - - - - - - -
15 58% 41.0 42.0 42.9 44.0 45.1 46.2 47.5 48.8 50.3 52.0 53.9 56.0 58.6 62.0 67.0 - - - - - - - - -
16 59% 41.0 41.9 42.8 43.8 44.8 45.9 47.1 48.3 49.7 51.2 52.8 54.7 56.9 59.5 62.8 67.8 - - - - - - - -
17 60% 41.0 41.8 42.7 43.6 44.6 45.6 46.7 47.8 49.1 50.5 52.0 53.6 55.5 57.7 60.3 63.6 68.6 - - - - - - -
18 62% 40.9 41.7 42.6 43.4 44.4 45.3 46.4 47.4 48.6 49.9 51.2 52.7 54.4 56.3 58.4 61.0 64.4 69.4 - - - - - -
19 63% 40.9 41.7 42.5 43.3 44.2 45.1 46.1 47.1 48.2 49.4 50.6 52.0 53.5 55.1 57.0 59.2 61.8 65.1 70.1 - - - - -
20 64% 40.8 41.6 42.4 43.2 44.0 44.9 45.8 46.8 47.8 48.9 50.1 51.3 52.7 54.2 55.8 57.7 59.9 62.5 65.8 70.9 - - - -
21 65% 40.8 41.5 42.3 43.0 43.9 44.7 45.6 46.5 47.5 48.5 49.6 50.7 52.0 53.4 54.9 56.5 58.4 60.6 63.2 66.5 71.5 - - -
22 66% 40.8 41.5 42.2 42.9 43.7 44.5 45.4 46.2 47.2 48.1 49.2 50.2 51.4 52.7 54.0 55.5 57.2 59.0 61.2 63.8 67.2 72.2 - -
23 67% 40.8 41.4 42.1 42.8 43.6 44.4 45.2 46.0 46.9 47.8 48.8 49.8 50.9 52.1 53.3 54.7 56.2 57.8 59.7 61.9 64.5 67.8 72.8 -
24 68% 40.7 41.4 42.1 42.7 43.5 44.2 45.0 45.8 46.6 47.5 48.4 49.4 50.4 51.5 52.7 53.9 55.3 56.8 58.4 60.3 62.5 65.1 68.5 73.5
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